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ABSTRACT 
Major depressive disorder is one of the most significant causes of disability worldwide. 
Currently, the main treatment options for depression are psychotherapy and 
antidepressant drugs that pharmacologically target the monoamine systems – such as 
serotonin transporter (SERT) blocker fluoxetine. It has been hypothesized that 
impairments in synaptic function and plasticity, caused for example by stress, could 
underlie the manifestation of depression. Moreover, in rodent models chronic treatment 
with antidepressant drugs has been shown to enhance plasticity of the adult brain via 
brain-derived neurotrophic factor (BDNF). The effects of BDNF mediated via its receptor 
tropomyosin receptor kinase B (TrkB) promote synapse function and thus could facilitate 
recovery from depression. Interestingly, antidepressant drugs with different main 
pharmacological targets seem to share the ability to activate the TrkB receptor, however, 
the mechanisms how antidepressant drugs activate TrkB are not known. 
The delayed onset of action and limited therapeutic efficacy of antidepressant drugs has 
promoted interest toward finding more rapid-acting and effective treatment options for 
depression. Electroconvulsive therapy has been the treatment of choice for treatment 
resistant depressed patients, however, side effects and the disrepute among general 
public has limited its use. Recently, subanesthetic doses of dissociative anesthetic 
ketamine have been shown to rapidly alleviate depression symptoms in depressed 
patients who do not respond to conventional antidepressant drugs. The effects of 
ketamine on mood appear already couple of hours after single intravenous infusion and 
last for about one week. Ketamine has been shown to induce mammalian target of 
rapamycin (mTOR) via BDNF-TrkB signaling, rapidly promote synaptogenesis and alter 
neural network function. Furthermore, in small human studies another anesthetic 
isoflurane has rapidly alleviated symptoms of depressed patients. Yet, the potential of 
isoflurane in the treatment of depression has not been studied in large clinical trials. 
Since TrkB receptor is involved in regulation of synaptic plasticity, drugs that act as 
agonists or positive allosteric modulators of TrkB could be potentially beneficial in the 
treatment of CNS disorders characterized by impaired plasticity. The first aim of our 
studies was to develop a platform suitable for high-throughput screening of compounds 
regulating TrkB activity. We developed an in situ ELISA (enzyme-linked immunosorbent 
assay) method that detects phosphorylated TrkB receptors from cultured cells. The main 
advantage of the in situ ELISA compared to conventional ELISA is that the cells are 
cultivated directly on the ELISA plate making the additional transfer step of the cellular 
material from the cell culture plate to the ELISA plate unnecessary. To further validate 
the in situ ELISA method, we conducted a proof-of-concept screening of a small chemical 
library and found several compounds that dose-dependently activated TrkB receptor or 
inhibited BDNF-induced TrkB activation. 
The second aim was to examine the mechanism how the antidepressant drugs activate 
TrkB. Interestingly, we found that antidepressant drugs activate TrkB independently of 
BDNF. Moreover, SERT, the main pharmacological target of fluoxetine, was not required 
for the fluoxetine-induced TrkB activation. Furthermore, the antidepressant-induced 
TrkB activation was developmentally regulated. The ability of antidepressants to activate 
TrkB appeared around postnatal day 12. Interestingly, at this same developmental 
timepoint (P12) the ability of BDNF to activate TrkB decreased dramatically.  
Finally, we aimed to characterize the neurobiological basis for the possible 
antidepressant effects of isoflurane. We found that brief isoflurane anesthesia rapidly 
and transiently activated the TrkB-mTOR signaling and produced antidepressant-like 
behavioral response in the forced swim test in a TrkB-dependent manner. Single 
isoflurane treatment also produced an antidepressant-like phenotype in behavioral 
paradigms that normally require chronic treatment with conventional antidepressant 
drugs, suggesting that isoflurane may have rapid antidepressant effects similar to 
ketamine. Moreover, isoflurane facilitated hippocampal long-term potentiation when 
measured 24 hours after the treatment and affected the general neural network function 
by increasing activity of the parvalbumin-positive inhibitory interneurons in the 
hippocampus.  
In conclusion, our results improve the understanding of the mechanism of action of 
conventional antidepressant drugs and provide plausible neurobiological basis for the 
antidepressant effects of isoflurane. Our findings also support examining further the 
potential of anesthetics in the treatment of depressed patients who do not respond to the 
current treatment options. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIIVISTELMÄ 
Masennus on merkittävä kansanterveydellinen ongelma, jonka kehittymiseen on 
ehdotettu liittyvän esimerkiksi pitkäkestoisen stressin aiheuttamia häiriöitä aivojen 
muovautuvuudessa ja hermosoluyhteyksien toiminnassa. Masennuksen hoito perustuu 
pääasiassa psykoterapiaan ja masennuslääkkeisiin. Kaikki kliinisessä käytössä olevat 
masennuslääkkeet vaikuttavat aivojen monoaminergisiin järjestelmiin, ja 
masennuslääkkeiden vaikutusten onkin pitkään ajateltu välittyvän yksinomaan näiden 
järjestelmien kautta. Eläinkokeissa masennuslääkkeiden on havaittu voimistavan 
aivojen muovautuvuutta aivoperäisen hermokasvutekijän (BDNF) välityksellä. BDNF 
osallistuu hermoyhteyksien toiminnan säätelyyn TrkB (tropomyosin receptor kinase B) 
–reseptorin välityksellä ja masennuslääkkeiden vaikutukset BDNF-TrkB –signalointiin 
saattavatkin osaltaan edesauttaa masennuksesta toipumista. Kyky aktivoida TrkB-
reseptoria vaikuttaisikin olevan yhteinen ominaisuus muutoin eri kohdemolekyyleihin 
vaikuttavilla masennuslääkkeillä. Tarkempaa mekanismia masennuslääkkeiden 
aikaansaaman TrkB-reseptorin aktivaation taustalla ei kuitenkaan vielä tunneta. 
Osa masennuspotilaista ei riittävästi hyödy nykyisistä masennuslääkkeistä ja 
masennuslääkkeiden terapeuttiset vaikutukset ilmenevät viiveellä. Tämän vuoksi 
masennuksen hoitoon yritetään jatkuvasti kehittää uusia, tehokkaampia ja nopeammin 
toimivia lääkkeitä.  Sähköhoito (ECT) on tällä hetkellä käytössä olevista hoitomuodosta 
tehokkain, mutta se aiheuttaa muistihäiriöitä ja sen käyttöä rajoittavat lisäksi 
voimakkaat ennakkoluulot. Viime aikoina nukutusaine ketamiinin on havaittu nopeasti 
(muutamassa tunnissa) lievittävän masennusoireita muihin hoitoihin reagoimattomilla 
potilailla. Ketamiinin masennusta lievittävien vaikutusten taustalla on esitetty olevan 
sen kyky aktivoida BDNF-TrkB-mTOR (mammalian target of rapamycin) –signalointia, 
nopeasti lisätä uusien hermosoluyhteyksien määrää ja muuttaa hermoverkkojen 
toimintaa. Ihmisillä tehdyissä tutkimuksissa on lisäksi havaittu toisen nukutusaineen, 
isofluraanin, lievittävän masennusoireita nopeasti. Isofluraanin tehoa masennuksen 
hoidossa ei ole kuitenkaan vielä tutkittu laajemmissa kliinisissä tutkimuksissa.  
TrkB-reseptorin välittämiä plastisuusvaikutuksia voitaisiin mahdollisesti hyödyntää 
myös muiden keskushermostosairauksien kuin masennuksen hoidossa. 
Tarkoituksenamme olikin kehittää menetelmä, jonka avulla voitaisiin seuloa TrkB-
reseptoriin vaikuttavia uusia molekyylejä. Kehitimme in situ ELISA (enzyme-linked 
immunosorbent assay) –menetelmän, joka tunnistaa TrkB-reseptorin fosforyloituneen 
eli aktivoituneen muodon solunäytteistä. In situ ELISA eroaa tavallisesta ELISAsta siten, 
että solut kasvatetaan suoraan ELISA-levyllä. In situ ELISA soveltuu myös suurten 
kirjastojen seulomiseen, koska siinä vältytään työläältä näytteiden siirrolta 
soluviljelylevyltä ELISA-levylle. Osoittaaksemme menetelmän soveltuvuuden 
seulomistarkoitukseen, seuloimme 2000 yhdisteen kirjaston ja identifioimme useita 
Trk-reseptoria aktivoivia sekä BDNF:n vaikutuksia estäviä yhdisteitä. 
Tämän jälkeen tutkimme, miten masennuslääkkeet saavat aikaan TrkB-reseptorin 
aktivoitumisen hiiressä. Yllättäen havaitsimme, että masennuslääkkeet aktivoivat TrkB-
reseptorin ilman BDNF:ä, transaktivaation välityksellä. Lisäksi fluoksetiinin 
aikaansaama TrkB-reseptorin aktivoituminen tapahtui ilman, että sen täytyi sitoutua 
pääasialliseen kohdemolekyylinsä serotoniinitransportteriin (SERT). 
Masennuslääkkeiden aikaansaama TrkB-reseptorin aktivoituminen oli myös 
kehityksellisesti säädeltyä ilmeten vasta 12 päivän ikäisillä hiirillä. Tässä samassa 
kehitysvaiheessa BDNF:n aikaansaama TrkB-reseptorin aktivoituminen taas väheni 
merkittävästi. 
Lopuksi selvitimme, minkälaisten neurobiologisten prosessien kautta nukutusaine 
isofluraanin mahdolliset masennusta lievittävät vaikutukset voisivat välittyä. 
Tutkimuksemme osoittivat isofluraanin aktivoivan hiiressä TrkB-mTOR –signalointia ja 
aiheuttavan pakotetussa uintitestissä (forced swim test) masennuslääkkeen kaltaisen 
käyttäytymisvasteen, joka välittyi TrkB-reseptorin kautta. Lisäksi yksi isofluraani-
nukutus sai aikaan masennuslääkkeen kaltaisen käyttäytymisvasteen testeissä, jotka 
normaalisti vaativat pitkäaikaisen käsittelyn masennuslääkkeillä. Tämä osoittaakin, että 
isofluraani saattaisi toimia ketamiinin tapaan nopeavaikutteisena masennuslääkkeenä. 
Kestotehostuminen (LTP, long-term potentiation) voimistui ja parvalbumiinia 
ilmentävien estävien välineuronien aktiivisuus lisääntyi hippokampuksessa 24 tuntia 
isofluraani-käsittelyn jälkeen, osoittaen että yhdellä nukutuksella on pitkäkestoisia 
vaikutuksia myös hermoverkkojen toimintaan.  
Tutkimustuloksemme tuovat lisää tietoa masennuslääkkeiden vaikutusmekanismeista ja 
voivat selittää, minkä vuoksi isofluraanilla saattaa olla masennusoireita lievittäviä 
vaikutuksia. Lisäksi tulostemme perusteella nukutusaineiden käyttökelpoisuutta muihin 
hoitoihin reagoimattomien masennuspotilaiden hoidossa kannattaisi tutkia lisää. 
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1. INTRODUCTION 
Major depression is the largest contributor to the worldwide disease burden when 
measured as years lost to disability. This occurs primarily because depression can persist 
for many years and a large number of individuals (~350 million) suffer from it (Smith, 
2014). Antidepressant drugs (AD) and psychotherapy are the main treatment options for 
depression, however, significant amount of depressed patients do not respond to the 
treatment. 
It has been suggested that stress-induced changes in neuronal connectivity and resulting 
disturbances in network function are important factors in the pathophysiology of 
depression (Castrén & Hen, 2013). Brain-derived neurotrophic factor (BDNF) and its 
receptor tropomyosin receptor kinase B (TrkB) are known to regulate neuronal plasticity, 
pathology of depression and the mechanism of action of ADs. ADs promote the 
expression of BDNF and activate its receptor TrkB (Nibuya et al., 1995a; Rantamäki et 
al., 2007; Saarelainen et al., 2003). Since BDNF and TrkB are involved in the regulation 
of neuronal excitability, cell survival and plasticity, the ability of ADs to increase their 
expression has been suggested to underlie the therapeutic effects of ADs.  
However, delayed onset of action and poor efficacy of ADs limits their therapeutic use. 
Significant attempts to find novel drugs for treatment of depression have been 
conducted. Electroconvulsive therapy (ECT) remains the treatment of choice for patients 
unresponsive to multiple trials with different ADs and psychotherapy. Recently, 
however, a subanesthetic dose of ketamine has been shown to rapidly alleviate 
depression symptoms and to reduce suicidal ideation in treatment resistant depressed 
(TRD) patients and BDNF-TrkB signaling has been shown to be involved in these 
therapeutic effects of ketamine (Autry et al., 2011; Berman et al., 2000; Zarate CA et al., 
2006). Ketamine, however, may produce hallucinogenic effects and has significant abuse 
potential, thus it is not an optimal drug to replace the conventional antidepressant 
treatments. Intriguingly, volatile anesthetic isoflurane has been shown to relieve 
depression symptoms of TRD patients as effectively as ECT but without the cognitive 
side effects characterized with ECT (Langer et al., 1985, 1995; Weeks et al., 2013).  
Altogether these preliminary findings encourage investigating further the antidepressant 
potential of anesthetics in animal models and human patients.  
In this thesis the role of BDNF and TrkB in the central nervous system and in the effects 
of antidepressant drugs will be discussed. In the experimental section we have developed 
tools to screen for novel TrkB activators, investigated the mechanisms of antidepressant-
induced TrkB activation, and dissected the neurobiological basis for the antidepressant 
effects of isoflurane.  
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2. REVIEW OF THE LITERATURE 
2.1 BDNF AND TRKB 
2.1.1 Discovery of neurotrophins 
The discovery of the first neurotrophin, the nerve growth factor (NGF), and the 
characterization of its effects on the survival and target innervation of subpopulation of 
neurons in the peripheral nervous system (PNS) were done by Rita Levi-Montalcini, 
Victor Hamburger and Stanley Cohen (Levi-Montalcini, 1987). These findings were 
seminal to the idea that the non-neural target tissue secretes factors that affect the 
survival of neurons innervating it; a concept nowadays known as the neurotrophic 
hypothesis (Bothwell, 2014). According to the hypothesis, now supported by massive 
amounts of experimental data, neurotrophins are released from the target tissue in very 
limited amounts allowing the survival of only a small number of neurons during early 
development (Bothwell, 2014).  
NGF alone was not sufficient to understand all of the neurotrophic effects detectable 
during early development, thus brain-derived neurotrophic factor (BDNF) was 
discovered. As the name implies, BDNF was first extracted from pig brain tissue (Barde 
et al., 1982), indicating that neurotrophins also act at the level of central nervous system 
(CNS). The characterization of the other members of the neurotrophin family - 
Neurotrophin-3 (NT-3) and Neurotrophin 4 (NT-4) - was facilitated by the technical 
development in molecular biology, especially the discovery of polymerase chain reaction 
(PCR), since the gene structures of already known neurotrophins could be exploited to 
find similar proteins (Hallböök et al., 1991; Maisonpierre et al., 1990a). Currently the 
mammalian neurotrophin family consists of four structurally and functionally similar 
members: NGF, BDNF, NT-3 and NT-4. 
The signaling effects of neurotrophins are mediated via the p75 neurotrophin receptor 
(p75NTR) and the Trk receptor tyrosine kinases. All the neurotrophins can activate the 
signaling via p75NTR, but their binding affinities to the Trk receptors are more specific: 
NGF binds to TrkA, BDNF and NT-4 to TrkB and NT-3 to TrkC (Klein et al., 1991a, 1991b, 
1992; Lamballe et al., 1991). 
Although all neurotrophins act as target-derived survival factors in the PNS during the 
development, their functions in the CNS appear much more diverse and complex. The 
literature review focuses on BDNF since it is the most abundant neurotrophin in the 
brain and it has been linked with the pathophysiology of depression, mechanism of 
action of antidepressant drugs and brain plasticity. These issues and the basic 
neurobiology of BDNF and TrkB will be introduced in the subsequent sections.  
2.1.2 Bdnf gene structure and regulation 
The bdnf gene consists of eight 5’ non-coding, regulatory exons and one 3’ coding exon 
(exon IX) (Aid et al., 2007) (Fig 1A). The complexity of the bdnf gene allows precise 
temporal and spatial regulation of BDNF expression. The exons are controlled by distinct 
promoters that can be differentially regulated. Importantly however, all the transcripts 
eventually encode the same BDNF protein. Various stimuli can activate different 
transcription factors, which can then bind to different promoter regions of the bdnf exons 
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resulting in transcription of specific bdnf transcripts (West et al., 2014).  Furthermore, 
the transcripts have distinct localization, stability and translational regulation inside the 
cell. Deletion of promoter regions IV and VI from the bdnf gene results in a robust 
reduction of bdnf expression in the hippocampus and prefrontal cortex (PFC), whereas 
deletion of promoter regions I and II reduces BDNF expression in the hypothalamus 
(Maynard et al., 2015). These studies support the area specific roles of the bdnf 
promoters.  
 
 
Fig 1. A Structure of the bdnf gene (modified from Aid et al. 2007). The grey are represents the 
protein coding region. B Structure of the BDNF protein showing the different domains and the N-
glycosylation site. 
 
The distinct effects of the individual bdnf transcripts is further supported by the altered 
behavior and serotonergic functions of mice in which BDNF production is disrupted from 
the promoters I, II, IV or VI (Maynard et al., 2015).  For example, exon I and II specific 
knock out mice show increased aggressive behavior whereas mice lacking exon IV or VI 
do not. It has been previously shown however, that bdnf deletion from the ventromedial 
and dorsomedial hypothalamus does not cause aggressive behavior (Unger et al. 2007), 
suggesting that the effects of BDNF on hypothalamic circuits regulating aggression are 
derived from developmental abnormalities in the network formation. Exon I knockouts 
show increased expression of the serotonin (5-HT) transporter (SERT), the 5HT2A 
receptor and parvalbumin in the prefrontal cortex (Maynard et al., 2015). Exon IV and 
VI knockouts have reduced gene expression of markers for GABAergic interneurons, e.g. 
parvalbumin (only in exon IV knockout mice), cortistatin and somatostatin in the PFC.  
Neuronal activity strongly regulates bdnf transcription. Specifically the expressions of 
bdnf exons I, II and IV are regulated in an activity-dependent manner (West et al., 2014). 
Bdnf exon IV expression is strongly induced by elevations in intracellular calcium 
concentration (Hong et al., 2008; Tao et al., 1998). Transcription factor cAMP response 
element binding protein (CREB) is an important mediator of the activity- and calcium-
dependent transcription of bdnf (Chen and Russo-Neustadt, 2009; Tao et al., 1998). 
Indeed, mutation in the CREB-binding site in the bdnf promoter IV impairs the activity-
dependent bdnf transcription (Hong et al., 2008). In addition, calcium-responsive 
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transcription factor (CaRF) regulates bdnf exon IV transcription in neurons in an 
activity-dependent manner (Tao et al., 2002).  
Potassium chloride and kainic acid are widely used agents to increase excitatory 
neurotransmission and neuronal activity. Stimulation with potassium chloride or kainic 
acid increased bdnf expression AMPAR- (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor) and calcium-dependently in cultured neurons (Zafra 
et al., 1990). Even though NMDA (N-methyl-D-aspartate) receptors were not required 
for these effects, NMDA receptor -mediated activity is important in more physiological 
conditions since NMDA antagonists can prevent increases in bdnf messenger ribonucleic 
acid (mRNA) normally observed during maturation in neuronal cultures (Zafra et al. 
1991). Most importantly, sensory stimuli, or lack thereof, strongly regulate bdnf 
transcription in vivo. For example, dark rearing decreases bdnf expression in the rat 
visual cortex but re-exposure to light quickly restores bdnf mRNA levels (Castrén et al., 
1992). Moreover, increased neuronal activity following physical exercise, drug treatment, 
or seizures increase bdnf transcription (Chen and Russo-Neustadt, 2009; Nibuya et al., 
1995a; Russo-Neustadt et al., 1999; Zafra et al., 1991). In contrast, pharmacologically-
induced neuronal inhibition or reduction of neuronal excitability decreases bdnf mRNA 
levels in vivo (Zafra et al. 1991). Bdnf transcription also appears to be stress-responsive 
since acute and chronic stress reduce hippocampal bdnf mRNA levels, while increasing 
bdnf expression in the hypothalamus and pituitary (Smith et al., 1995a, 1995b). 
2.1.3 Expression and localization of BDNF 
BDNF protein is widely expressed in the brain, with highest levels detected in the 
cerebral cortex and the hippocampus (Conner et al., 1997; Ernfors et al., 1992; Hofer et 
al., 1990). The expression of BDNF was initially thought to be limited to neurons (Zafra 
et al., 1990) but it is now widely accepted that brain microglia – particularly activated 
microglia – can take up and release BDNF as well (Parkhurst et al., 2013). BDNF seems 
to be expressed mainly in principal glutamatergic neurons but not in inhibitory 
interneurons (Gorba and Wahle, 1999; Kuczewski et al., 2009). Although certain areas 
of the brain essentially lack bdnf mRNA expression, transported BDNF protein can be 
detected in these areas (Altar et al., 1997). 
BDNF expression in the brain is strongly regulated during development. The expression 
of bdnf mRNA gradually increases during early postnatal life, plateauing in rodents 
around 3 weeks of age (Maisonpierre et al., 1990b; Rauskolb et al., 2010). In the human 
dorsolateral prefrontal cortex (dlPFC) bdnf expression increases about one-third from 
postnatal levels to adulthood peaking during early adulthood (around 22 years of age) 
(Webster et al., 2002). Importantly, the peak of bdnf expression in the dlPFC is seen at 
the age when the structural and functional maturation of the PFC occurs. In the 
hippocampus bdnf mRNA levels seem to stay relatively constant during human life span, 
including the aging brain (Webster et al., 2006).  
In cultured neurons BDNF protein is found in the soma, as well as also in axons and in 
dendrites (Adachi et al., 2005; Conner et al., 1997; Kohara et al., 2001). In vivo the 
dendritic expression of bdnf mRNA has been demonstrated in apical dendrites of 
hippocampal CA1 neurons (An et al., 2008; Tongiorgi et al., 2004). BDNF protein has 
been primarily located in dense-core vesicles of the presynaptic terminals of excitatory 
neurons (Dieni et al., 2012). These partially controversial findings of in vitro versus in 
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vivo BDNF localization may be explained by the differential and complex regulatory 
processes of synapse formation and intracellular trafficking of neurons in the adult brain 
compared to neuronal cultures. 
The retrograde transport of neurotrophins in the PNS is the basis for the neurotrophic 
hypothesis, where survival of the innervating neurons is regulated by the neurotrophin 
released from the target tissue in a constitutive manner. Although the situation is more 
complex in the brain, retrograde transport of BDNF has been demonstrated for example 
in the eye, from where BDNF could be transported into the isthmo-optic nucleus (von 
Bartheld et al., 1996). Striatal infusion of BDNF resulted in retrograde BDNF transport 
to brain regions known to project to striatum e.g. thalamic areas and substantia nigra 
pars compacta (Mufson et al., 1994). Application of BDNF to dendrites but not to axons 
induced immediate early gene expression (c-fos, Arc) in the soma; indicating that BDNF-
induced signals from dendrites are conveyed to the soma (Cohen et al., 2011). 
One of the first studies showing anterograde transport of BDNF was done by Zhou et al. 
in primary sensory neurons (Zhou and Rush, 1996). BDNF was shown to be transported 
both retrogradely and anterogradely, functioning as a modulator of synaptic 
transmission or as a trophic factor for the organs that the neurons were innervating. 
Kohara et al. (2001) demonstrated the anterograde axonal transport of BDNF in cultured 
cortical neurons. Follow-up studies from the same group showed that the transport of 
BDNF in axons is mainly anterograde, whereas in dendrites BDNF seemed to be not 
moving at all or moving back and forth in a slower fashion (no clear retrograde transport) 
(Adachi et al., 2005). In the striatum BDNF protein, but not mRNA is present; indicating 
that BDNF is transported to the striatum anterogradely from the cortex by projection 
neurons (Kolbeck et al., 1999). In the nucleus accumbens bdnf mRNA levels are low and 
BDNF protein is transported there mainly from the ventral tegmental area (Altar et al., 
1997; Conner et al., 1997; Horger et al., 1999). In BDNF knockout animals the number of 
parvalbumin-expressing neurons in the striatum was reduced at two weeks of age 
suggesting that the BDNF transported to the area is regulating the maturation or survival 
of this neuronal population (Altar et al., 1997). Noradrenergic neurons projecting to the 
cortex were shown to express BDNF and transport it anterogradely to the cortex to 
regulate the survival of the target neurons (Fawcett et al., 1998). 
2.1.4 Processing and secretion of BDNF protein  
BDNF is synthesized as pre-proBDNF, a precursor protein that is further processed in 
the endoplasmic reticulum to proBDNF (Greenberg et al., 2009) (Fig 1B). The proBDNF 
isoform is then N-glycosylated and glycosulfated (Mowla et al., 2001). The glycosylation 
increases the stability of proBDNF during processing and subcellular trafficking. The 
pro-domain participates in the proper folding and intracellular sorting of BDNF 
(Brigadski et al., 2005; Lee et al., 2001b). The translated protein is further processed in 
the Golgi and trans-Golgi network and directed to synaptic vesicles for release. The 
proBDNF isoform can be cleaved to produce the mature form of BDNF (mBDNF) inside 
the cell in trans-Golgi network or post-Golgi compartments by pro-convertases and 
furin, or outside the cell by matrix metalloproteinases (MMP-7) or plasmin (Lee et al., 
2001b; Pang et al., 2004; Seidah et al., 1996). The efficacy of proBDNF cleavage to 
mBDNF seems to vary during development. Postnatally and during adolescence both 
proBDNF and mBDNF are expressed at similar levels, but in the adult brain the mature 
form dominates. Furin is the main cleavage enzyme of the constitutive pathway guiding 
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the neurotrophins to the constitutive pathway (for example in fibroblasts) (Mowla et al., 
1999). The processing enzymes in the regulated and constitutive secretion pathways are 
different and the cleavage of BDNF occurs in different subcellular compartments. In CNS 
neurons BDNF is primarily directed to the regulated secretion pathway where furin is 
not the essential enzyme for the processing of BDNF in the CNS neurons (Mowla et al., 
1999). In neurons the pro-convertases (PC) cleave the neurotrophin precursors inside 
immature secretory vesicles in the trans-Golgi and are involved in the processing of 
neurotrophins in the regulatory pathway. In the hippocampus and amygdala, PC7, an 
enzyme of the proprotein convertase family, is involved in the intracellular processing of 
proBDNF to BDNF (Wetsel et al., 2013). 
In non-neuronal tissue BDNF appears to be constitutively released but in the brain the 
secretion is mainly regulated through activity-dependent mechanisms (Mowla et al., 
1999). BDNF is stored in dense-core vesicles in the membrane fraction of synaptic 
terminals (Fawcett et al., 1997). In vitro BDNF can be released both pre- and 
postsynaptically and in cultured hippocampal neurons BDNF has been detected in 
dendrites and axons (Adachi et al., 2005; Jakawich et al., 2010; Matsuda et al., 2009). 
Interestingly pre- and postsynaptic release of BDNF seems to require different patterns 
of stimulation. For example, the dendritic release of BDNF is dependent on calcium 
influxes via NMDA receptors and L-type voltage-gated calcium channels. Furthermore, 
BDNF can induce its own release via a positive feedback loop including stimulation of 
TrkB receptors, activation of phospholipase C-gamma (PLCγ) and mobilization of 
intracellular calcium stores (Canossa et al., 1997, 2001).  Stimulation of metabotropic 
glutamate receptors can also activate PLCγ  and induce calcium release from intracellular 
storages via inositol trisphosphate (IP3) resulting in BDNF release (Canossa et al., 2001). 
Interestingly, the effect of glutamate on BDNF release can be blocked with AMPA 
receptor antagonists but not NMDA receptor antagonists, and AMPA can increase BDNF 
release from hippocampal slices and cultured neurons. 
In vivo BDNF is co-expressed with the cleaved pro-peptide in dense core vesicles 
presynaptically in the hippocampus, indicating that BDNF is cleaved inside the vesicles 
and possibly released together with the cleaved pro-domain (Dieni et al., 2012). Since 
there are enzymes that are able to cleave proBDNF to mBDNF also extracellularly, it has 
been debated whether proBDNF can be released from the neurons or if it is processed to 
mature BDNF in secretory vesicles before release. Lee et al. (2001b) suggested that 
proBDNF is released from endothelial cells and can then be processed by tissue 
plasminogen activator (tPA) and MMPs, and Chen et al. (2004) showed that proBDNF 
is primarily released from the PC12 cells but is then quickly cleaved outside the cell. In 
another study where proBDNF and mBDNF levels were measured in hippocampal 
neuron cultures from the cell lysate and medium (secreted), the authors found that in 
the presence of plasmin inhibitor α2-antiplasmin and in the culture conditions where 
glial cell amount is reduced, proBDNF but not mBDNF is found in the medium, 
supporting the importance of extracellular cleavage of secreted proBDNF (Yang et al., 
2009). When hippocampal neurons were infected with proBDNF expressing virus, 
proBDNF was secreted into the medium and the amount of proBDNF in the medium 
increased over time (Mowla et al., 1999). Also cultured cortical neurons were shown to 
release proBDNF into the medium (Teng et al., 2005). In a study by Matsumoto et al. 
(2008) the authors suggest that in hippocampal neurons endogenous proBDNF is 
processed into BDNF already intracellularly (Matsumoto et al., 2008). Altogether the 
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release of BDNF/proBDNF has been mainly studied in overexpression systems or non-
neuronal cell lines using transfection of BDNF complementary DNA (cDNA), and 
Matsumoto et al. suggest that in these situations the cells may lack the machinery for 
proper processing of proBDNF or the capacity to process proBDNF to mature BDNF is 
saturated, which could lead to biased results. Thus, it is difficult to reliably measure 
BDNF secretion in vivo. 
2.1.5 TrkB gene and mRNA 
The BDNF receptor TrkB was first cloned from mouse brain tissue by virtue of its high 
sequence homology to the NGF receptor TrkA (Klein et al., 1989). The TrkB gene 
(NTRK2) is capable of producing multiple transcripts including the full-length catalytic 
tyrosine kinase receptor but also TrkB receptor variants that lack the catalytic kinase 
domain (Klein et al., 1990; Middlemas et al., 1991; Stoilov et al., 2002). The full-length 
TrkB receptor consists of an extracellular ligand-binding domain, a transmembrane 
anchoring domain and an intracellular domain that includes the highly conserved 
catalytic kinase domain (Klein et al., 1990). The truncated TrkB receptors (TrkB.T1 and 
TrkB.T2) share similar extracellular and transmembrane domains to the full-length 
receptor but have only a short intracellular part consisting of a unique sequence of amino 
acid residues. In the human brain there is no expression of TrkB.T2, however, an 
additional isoform, TrkB.Shc, is present and lacks the tyrosine kinase domain but 
contains the intracellular Shc site (Stoilov et al., 2002). In mouse a TrkB receptor isoform 
lacking the extracellular leucine rich repeats completely or in part has been identified 
(Ninkina et al., 1997). 
The human TrkB gene is large, consisting of 24 exons that produce multiple mRNAs 
which can produce up to 10 different protein isoforms (Stoilov et al., 2002) (Fig 2A). 
Three isoforms, TrkB.FL, TrkB.T1 and TrkB.Shc are predominantly expressed at the 
protein level. The exons 6-15 of the TrkB gene encode the extracellular domain, the 
transmembrane domain, and a part of the juxtramembrane domain of the receptor. Exon 
16 includes a stop codon and is part of the TrkB.T1. Exons 17-18 encode the intracellular 
juxtramembrane part and exon 19 is an alternative terminating exon involved in the 
TrkB.Shc. Exons 20-24 encode the tyrosine kinase domain and the PLCγ site of the 
receptor. 
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Fig 2. A Exon structures of the three predominant TrkB isoforms: Full-length TrkB, TrkB.Shc 
lacking the tyrosine kinase domain but containing the Shc binding site and TrkB.T1 lacking the 
intracellular domains. B TrkB protein domains; C, cysteine rich region; Leu, leucine rich region; 
IG-L, immunoglobulin like-domain; TMD, transmembrane domain; Shc, Shc binding site; TKD, 
tyrosine kinase domain; PLCγ, PLCγ binding site. Modified from. Luberg et al. 2010. 
 
In humans, additional N-terminal truncated TrkB receptors have been identified (Luberg 
et al., 2010). These receptors lack the signal peptide that targets the receptors to the 
membrane and also the leucine-rich repeats (LRR) and one cysteine-rich domain from 
the extracellular domain of the receptor. The N-terminal truncated TrkB receptors can 
be phosphorylated even though they are not targeted to the membrane and most are 
unable to be activated by BDNF (Luberg et al., 2010).  
2.1.6 Functional domains and post-transcriptional processing of TrkB 
The extracellular domain of Trk receptors consists of a membrane-targeting signal 
peptide, two cysteine clusters that are located around LRRs followed by two 
immunoglobulin G (IgG)-like structures adjacent to the transmembrane domain 
(Schneider and Schweiger, 1991) (Fig 2B). The intracellular domains of TrkB include a 
tyrosine kinase domain and tyrosine motifs. Tyrosine phosphorylation controls the 
kinase activity of TrkB receptors and can regulate the binding of adaptor molecules to 
the receptor (Segal et al., 1996). The catalytic domain inside the tyrosine kinase domain 
is highly conserved among all the receptor tyrosine kinases (Klein et al., 1989; Lee et al., 
2001a; Segal et al., 1996). The IgG-like domain adjacent to the transmembrane domain 
acts as a binding site for neurotrophins and determines the ligand specificity of the 
receptor (Urfer et al., 1995). Neurotrophin binding to this domain can induce activation 
of the catalytic tyrosine kinase domain of the receptor. The other IgG domain and the 
leucine- and cysteine-rich repeats also seem to participate in ligand binding either 
directly or by inducing conformational changes (Huang and Reichardt, 2003; Ninkina et 
al., 1997). In general, the LRRs are thought to participate in protein-protein interactions. 
Deletion of the LRRs prevents the ligand from binding to TrkB and blocks the survival 
enhancing effects of BDNF in serum-depleted NIH3T3 cells (Ninkina et al., 1997). 
Specifically the second LRR of TrkB seems to bind BDNF (Windisch et al., 1995). Co-
expression of p75NTR can alter the extracellular sites of TrkB required for BDNF binding 
(Zaccaro et al., 2001). In the absence of p75NTR BDNF binds to the IgG-C2 domain of 
TrkB but when p75NTR and TrkB are expressed together, BDNF binding requires the LRR 
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and the cysteine 2 domains. Juxtamembrane domain (short sequence of about 80 amino 
acids that is located between the transmembrane and tyrosine kinase domain) of TrkB 
regulates the internalization of the receptor after ligand binding (Sommerfeld et al., 
2000). The extracellular domain of TrkB can be N-glycosylated and the glycosylation of 
the receptor appears to increase during early development (Fryer et al., 1996; Haniu et 
al., 1995). Glycosylation is required for the localization of the Trk receptors to the cell 
membrane and can inhibit ligand-independent activation of the receptor (Watson et al., 
1999a) 
2.1.7 Expression and subcellular localization of TrkB 
TrkB receptor is widely expressed in both the peripheral and central nervous systems. In 
situ hybridization analysis has shown that trkB transcripts are expressed in the cerebral 
cortex, hippocampus, thalamus, choroid plexus, granular layer of the cerebellum, brain 
stem and spinal cord (Klein et al., 1993). In the PNS trkB transcripts have been detected 
in the cranial ganglia, retina, ophthalmic nerve, vestibular system, multiple facial 
structures, submaxillary glands and dorsal root ganglia. TrkB protein is found in 
olfactory bulb, hippocampus, thalamus, hypothalamus, septum, basal ganglia, midbrain 
nuclei and cerebellum (Yan et al., 1997).  
The expression patterns of the full-length and truncated TrkB receptors differ in the CNS. 
During early development TrkB.FL is the main receptor in the brain and is highly 
expressed in the dendrites; however, around postnatal day 10-15 (P10-P15) the 
expression of the TrkB.T1 receptor increases and exceeds the TrkB.FL especially in 
cortical areas (Fryer et al., 1996). In human prefrontal cortex the expression of TrkB.FL 
mRNA and protein peaks in toddlers and decreases slightly with aging, whereas the 
expression of the TrkB.T1 mRNA is regulated the opposite way with lowest expression 
levels in toddlers (Luberg et al., 2010). The TrkB.T1 protein expression seems to increase 
until teenage years after which it declines slightly. TrkB.Shc expression is low compared 
to the other two isoforms and the expression is reduced during aging compared to the 
expression levels in infants (Luberg et al., 2010). 
Functional full-length TrkB receptors can be found in postsynaptic densities (Wu et al., 
1996). TrkB receptors are found in axons and dendrites intracellularly and on the cell 
surface throughout development (Gomes et al., 2006). During maturation TrkB 
receptors localize to excitatory synapses in cortical neurons. The expression pattern of 
TrkB in interneurons and their responsiveness to neurotrophins varies during 
development (Gorba and Wahle, 1999). The TrkB receptor is not expressed by all types 
of interneurons but especially interneurons expressing parvalbumin coexpress TrkB  and 
BDNF-induced TrkB activation can promote parvalbumin expression via 
phosphoinositide 3-kinase (PI3K) signaling in early developmental timepoints (Patz et 
al., 2004). 
In cultured cells the truncated form of TrkB was heavily expressed on the cell surface in 
normal conditions but high levels of the full-length receptor were found in granular 
structures near the cytoplasm, suggesting that the majority of TrkB receptors are located 
inside the cell (Haapasalo et al., 2002). Similarly to BDNF, the synthesis, expression and 
intracellular transport of TrkB is regulated by neuronal activity (Merlio et al., 1993). Du 
et al. (2000) found that in cultured neurons TrkB receptors are mainly located in the 
cytoplasm and after electrical stimulation are recruited heavily to the membrane. 
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Apparently the receptors can be quickly translocated to the membrane from intracellular 
pools e.g. by BDNF stimulation or as a result of increased neuronal activity. In 
hippocampal neurons high frequency electrical stimulation induced surface expression 
of both the full-length and truncated TrkB receptors in a calcium- and 
calcium/calmodulin-dependent protein kinase II (CaMKII)-dependent manner (Du et 
al., 2000). Increase in calcium concentration leads to a cyclin-dependent kinase 5 (Cdk5) 
-dependent phosphorylation of the receptor at serine 478 which induces TrkB insertion 
into the cell membrane (Zhao et al., 2009). In cultured retinal ganglion cells and spinal 
motor neurons full-length TrkB receptors were inserted into the cell membrane after an 
increase in the amount of intracellular cyclic adenosine monophosphate (cAMP) (Meyer-
Franke et al., 1998). TrkB can also be inserted to the cell membrane after intracellular 
transactivation (Puehringer et al., 2013). It has been suggested that TrkB could act as a 
“synaptic tag” for plasticity promoting proteins (e.g. BDNF) to promote late-phase long-
term potentiation (L-LTP) since its expression on the plasma membrane increases after 
neuronal activity thereby marking active synapses (Lu et al., 2011). 
In addition to the insertion of TrkB into the cell membrane, neuronal activity and 
increase in intracellular calcium concentration regulate the internalization of TrkB 
receptors (Du et al., 2003). The kinetics of the receptor insertion to the membrane and 
its subsequent internalization can define the signaling pathways and other downstream 
actions of the receptor. A short treatment (15 s) with potassium chloride (KCl) did not 
increase TrkB surface expression in hippocampal primary neurons or TrkB.TK+ 
transfected N2a cells but BDNF did (Haapasalo et al., 2002). However, a 5 minute 
treatment with BDNF already reduced the surface expression of TrkB and the levels 
remained low for at least 24h, possibly due to endocytosis following receptor activation. 
Pretreatment of neuronal cell cultures with KCl prevented the decrease in TrkB surface 
expression that normally occurs after BDNF stimulation elongating the effect of BDNF 
on TrkB signaling, including phosphorylation of the receptor and its downstream targets 
extracellular signal-regulated kinase (ERK), protein kinase B (Akt) and PLCγ (Guo et al., 
2014). Inserting more TrkB receptors to the cell membrane compensates for the 
endocytosis occurring after ligand binding, and the TrkB signaling shifts from a transient 
event to sustained state.  
After endocytosis receptors are brought back to the membrane, degraded or transported 
towards the cell soma depending on whether the receptors are targeted to recycling 
endosomes, early endosomes or late-endosomes/lysosomes (IJzendoorn, 2006). 
TrkB.T1 and TrkB.FL receptors seem to be differentially recycled after BDNF-induced 
endocytosis with TrkB.FL receptor degraded (targeted to the lysosomes) more quickly 
than TrkB.T1 (Huang et al., 2009). The Rab11-positive endosomes regulate dendritic 
trafficking of the TrkB receptors after ligand binding and have an important role in the 
dendritic branching promoting effects of BDNF (Lazo et al., 2013). The Rab11-positive 
endosomes carrying TrkB receptor enrich to dendrites and increase TrkB expression in 
the plasma membrane (Watson et al., 1999b). 
Recently, cell-surface protein SLIT- and NTRK-like protein 5 (Slitrk5) has been 
implicated in the regulation of BDNF-induced TrkB signaling (Song et al., 2015). The 
extracellular LRR domain 1 of Slitrk5 specifically interacts with the LRR-domain of TrkB 
receptors after BDNF stimulation. In the absence of Slitrk5 BDNF stimulation induced 
normal TrkB phosphorylation, however, prolonged BDNF treatment did not produce 
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increase in primary dendrite formation as was seen in wild type neuronal cultures. The 
authors found that TrkB degradation was increased in the absence of Slitrk5 due to 
reduced targeting of TrkB to recycling endosomes, which are responsible for the 
recycling of the endocytosed receptors back to the membrane. These findings implicate 
Slitrk5 in targeting of TrkB to recycling endosomes and regulation of TrkB signaling. 
Receptor internalization and the following dynein-dependent transport of TrkB receptor 
from axon to soma (retrograde transport) are necessary for its survival-promoting effects 
in sensory neurons (Heerssen et al., 2004). The first observation of retrograde transport 
of activated Trk receptors was done using sciatic nerve injury, after which the 
phosphorylated Trk receptors were accumulating in the distal side of the injury 
indicating that the receptors were transported in clathrin-coated vesicles from the axon 
terminal towards the soma (Bhattacharyya et al., 1997). In addition, anterograde 
transport of TrkB following sciatic nerve injury has been reported (Yano et al., 2001). 
2.1.8 TrkB activation by BDNF and downstream signaling 
TrkB is a receptor tyrosine kinase and thus catalyzes upon activation transfer of a 
phosphate group to a tyrosine of another protein. TrkB receptors form homodimers upon 
ligand binding and this allows the receptors to phosphorylate tyrosines 706 and 707 in 
each other’s catalytic domain resulting in increased kinase activity of the receptor 
(Reichardt, 2006). In addition to the catalytic domain, other tyrosines of the receptor 
can be phosphorylated with the most extensively studied phosphorylation sites being 
Y515 and Y816  (Middlemas et al., 1994; Segal et al., 1996). Phosphorylated Y515 and 
Y816 (pY515 and pY816, respectively) can serve as docking site for Src homology 2 (SH2) 
adaptor proteins and phosphotyrosine binding domain containing proteins. Shc, Frs2 
(fibroblast growth factor receptor substrate 2) and PLCγ are the major interactor 
proteins directly binding to TrkB receptors and activating Trk-associated signaling 
pathways Ras, PI3k and PLCγ1 (Obermeier et al., 1993) (Fig 3).  
Shc binding to pY515 can activate signaling via PI3K and Ras by inducing a cascade of 
protein-protein interactions that further recruit serine/threonine kinases Akt and ERK 
(Hallberg et al., 1998; Obermeier et al., 1994). ERK can also be activated by signaling 
initiated by PLCγ binding to pY816 in TrkB (Stephens et al., 1994). Shc binding site 
signaling is linked to survival and axon outgrowth (Atwal et al., 2000). The Shc-PI3K-
Akt pathway and the Shc-Ras-Raf-ERK pathway both promote survival and 
differentiation (Yao and Cooper, 1995). In addition to Shc also Frs2 can bind to pY515. 
Frs2 interacts with Shp2 and Grb2 to induce ERK activation via Ras (Easton et al., 2006). 
It has been suggested that competition of Shc and Frs2 for the binding site could regulate 
the induction of proliferation vs. differentiation by the neurotrophins (Meakin et al., 
1999). The survival promoting effects of ERK are mediated via inhibition of pro-
apoptotic factors and increases in transcription of pro-survival factors (Bonni et al., 
1999). BDNF-TrkB-ERK signaling promotes dendritic growth and increases the number 
of spines in a subgroup of hippocampal neurons (Alonso et al., 2004). The PI3K-Akt 
pathway leads to activation of mTOR which regulates P70S6k and 4eBP1 to promote 
translation of proteins that affect cell survival, proliferation, differentiation and dendritic 
growth (Kumar et al., 2005; Takei et al., 2004).  
In addition to activating ERK, BDNF-TrkB signaling also induces the translocation of 
ERK to the nucleus and thus affects the transcription factors regulated by ERK, (e.g. 
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cyclic AMP response element-binding protein, CREB) (Patterson et al., 2001; Ying et al., 
2002). ERK cannot, however, directly phosphorylate CREB but requires Rsk to 
phosphorylate the serine 133 in CREB (Watson et al., 2001). CREB is one of the 
transcription factors linked to increased transcription of genes required for late-phase 
LTP and cell survival (Minichiello et al., 2002; Watson et al., 2001). 
Minichiello et al. generated a genetically modified mouse  with a point mutation at the 
Shc binding site of TrkB receptor (Y515 → phenylalanine (F)) (Minichiello et al., 1998). 
Cultured nodose and trigeminal ganglion neurons from these mice responded poorly to 
NT4 stimulation, suggesting that the Shc site activation is important for NT4 induced 
TrkB activation. In vivo, neurons known to depend on NT4 signaling were missing from 
TrkBY515F mice, however, most of the neurons that are lost in BDNF knockout animals 
were not affected in the mice with the Shc site mutation. ERK signaling is significantly 
reduced in TrkBY515F mice but CREB activation by BDNF stimulation appears to be 
normal (Minichiello et al., 1998, 2002). In contrast to the findings in cultured neurons 
the TrkBY515F mice did not show any deficits in the differentiation of CNS neurons, 
however, a mutation in the Shc site impaired axonal regeneration in vivo (Hollis et al., 
2009; Minichiello et al., 1998). 
The PLCγ1 binding site (Y816) of TrkB is in close proximity to the C-terminal region of 
the receptor and can be phosphorylated by ligand binding (Middlemas et al., 1994). Upon 
binding to pY816 the membrane-bound enzyme PLCγ is activated and can then hydrolyze 
phosphatidyl(4,5)inositolbisphosphate (PIP2) to second messengers diacylglycerol 
(DAG) and IP3 (Carpenter and Ji, 1999). DAG is a lipid that cannot diffuse into the 
cytoplasm but stays in the plasma membrane and activates protein kinase C (PKC) 
signaling. In contrast, IP3 can enter the cytoplasm and activate the release of calcium 
from the intracellular storages.  PKC activation and calcium release can lead to the 
activation of ERK, CaMKIV, and CREB and to release of neurotrophins (Canossa et al., 
2001; Finkbeiner et al., 1997; West et al., 2001). BDNF can potentiate excitatory synaptic 
transmission by increasing intracellular calcium concentration via TrkB-PLCγ-IP3-PKC 
signaling (Carmignoto et al., 1997; Levine et al., 1995; Li et al., 1998). In contrast to Y515, 
Y816-mediated signaling seems to be required for synaptic plasticity, especially for 
hippocampal long-term potentiation (Korte et al., 2000; Minichiello et al., 2002).  
TrkB-mediated PLCγ activation is also required for epileptogenesis (Gu et al., 2015; He 
et al., 2010). TrkB Y816 phosphorylation is increased during status epilepticus and 
preventing the signaling of the Y816-residue reduced PLCγ activation and prevented the 
epileptogenesis in a kindling model (He et al., 2010). Instead of blocking the TrkB 
receptor, inhibiting just the coupling of PLCγ to pY816 after chemically induced seizures 
prevents the epileptogenesis but does not impair the TrkB-mediated promotion of 
survival (Gu et al., 2015). 
In the PNS neurotrophin-induced activation of TrkB receptors in the nerve terminal 
results in endocytosis of the receptor-ligand complex and retrograde transport of the 
complex to the soma resulting in CREB activation and induction of immediate-early gene 
c-fos (Watson et al., 1999b). The retrograde transport of activated Trk receptors recruits 
specific signaling pathways involving ERK5 to mediate the survival promoting effects in 
the soma, suggesting that the location of TrkB activation also controls the downstream 
signaling pathways (Watson et al., 2001). Clathrin- and dynamin-dependent endocytosis 
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of TrkB receptors after BDNF stimulation has been shown to be important for BDNF-
induced PI3K-Akt signaling (Zheng et al., 2008).  
 
 
 
Fig 3. The main signaling pathways of the TrkB neurotrophin receptor. The TrkB receptor 
can be phosphorylated upon BDNF binding to the catalytic domain Y706/7, the Shc binding site 
Y515, and the PLCγ1 binding site Y816. The main pathways include Shc-PI3K-Akt, Shc-PI3K-
Ras-Raf-ERK and PLCγ1-IP3–PKC-CaMKIV that promote survival, differentiation, calcium 
release and initiation of transcription and translation.  
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2.1.9 Signaling of the truncated TrkB receptor 
Alternative splicing of the TrkB transcript results in the truncated receptors TrkB.T1 and 
TrkB.T2 that lack the intracellular tyrosine kinase domain but have small intracellular 
domains of 23 and 21 amino acids, respectively (Baxter et al., 1997; Klein et al., 1990). 
The truncated TrkB receptors can bind and internalize BDNF, however, due to the lack 
of tyrosine kinase domain the canonical neurotrophin signaling responses cannot be 
activated. BDNF stimulation of Xenopus oocytes transfected with TrkB.FL, TrkB.T1 or 
TrkB.T2 increased calcium efflux in a phosphatidylinositol dependent manner only in 
TrkB.FL transfected cells indicating that BDNF is able to activate this signaling only via 
tyrosine kinase containing TrkB receptors (Eide et al., 1996).  
When discovered, the truncated Trk receptors were thought to act as “simple” scavengers 
which limit the diffusion of neurotrophins since they are expressed widely in non-
neuronal tissues and can internalize BDNF after binding (Biffo et al., 1995). However, 
when the truncated receptor is expressed together with the full-length receptor it can 
form a heterodimer and inhibit the tyrosine kinase activity of TrkB.FL in a dominant-
negative manner (Eide et al., 1996; Haapasalo et al., 2001). The truncated receptors can 
reduce the surface expression of the full-length TrkB and thus regulate the availability of 
TrkB receptors to its ligands (Haapasalo et al., 2002). Because of their dominant negative 
function truncated receptors can negatively affect the survival role of BDNF (Ninkina et 
al., 1996). In vivo deletion of truncated TrkB receptors could partially rescue the 
phenotype of BDNF heterozygous knockout mice suggesting that the truncated TrkB 
receptor negatively regulates the full-length TrkB signaling when expressed at 
physiological levels (Carim-Todd et al., 2009). Moreover, overexpression of TrkB.T1 
reduced TrkB phosphorylation in vivo (Saarelainen et al., 2000). 
The effects of the truncated TrkB receptor are not limited to the regulation of the TrkB.FL 
signaling; they can also initiate intracellular signaling themselves. The small intracellular 
domains of the truncated receptors are required for this signaling (Baxter et al., 1997). 
BDNF stimulation can induce release of calcium from intracellular storages through 
TrkB.T1-activated IP3 signaling in the absence of TrkB.FL (Rose et al., 2003). More 
precisely, Rho GDI1 can bind the intracellular domain of TrkB.T1 and upon ligand 
binding dissociates from TrkB.T1 and activates other Rho GTPases that initiate changes 
in astrocytic function (Fenner, 2012). 
2.1.10 TrkB transactivation 
Receptor transactivation occurs independently of the ligand binding via activation of 
intracellular signaling events. Studies concerning the transactivation of Trk receptors 
have been mostly done in vitro and it is yet to be confirmed whether the same 
phenomena exists in physiological conditions in vivo. The first demonstrations of Trk 
receptor transactivation came from studies done in PC12 cells and primary hippocampal 
neurons, where G-protein coupled receptor (GPCR) ligands adenosine and pituitary 
adenylate cyclase-activating polypeptide (PACAP) were shown to activate Trk receptors 
without direct binding to the receptors or effects mediated via neurotrophins  (Lee and 
Chao, 2001; Lee et al., 2002). The activation was mediated by G-protein coupled 
adenosine A2 or PAC1 receptors and occurred relatively slowly, requiring a minimum of 
90 minutes. Adenosine and PACAP can also activate the PI3k-Akt-pathway via Trk 
receptors and to mediate cell survival. The effects of transactivation on ERK 
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phosphorylation are somewhat controversial since PACAP stimulation resulted in a 
sustained phosphorylation of ERK whereas adenosine stimulation did not. Intracellular 
calcium chelator EGTA and protein phosphatase 1 (PP1) (and PP2, Rajagopal and Chao 
2006) blocked the effects, suggesting that intracellular calcium and Src family members 
could be involved in the transactivation mechanism. The specific member of the Src 
family kinases involved in Trk transactivation is suggested to be Fyn (Rajagopal and 
Chao, 2006). Phosphorylation of Fyn is seen with similar temporal pattern as Trk 
activation, and it also requires increases in intracellular calcium concentration and can 
be blocked by PP1.  Fyn was also shown to interact with Trk receptor juxtamembrane 
region, but this interaction is not dependent on Trk kinase activity.  Also inhibiting 
transcription and translation with actinomycin D and cycloheximide, respectively, 
abolished the effect of GPCR ligands on Trk phosphorylation (Rajagopal et al., 2004). 
The ability of adenosine A2A receptor agonist to transactivate TrkB receptors was later 
demonstrated in vivo and the TrkB transactivation was crucial for the survival promoting 
effects of A2A agonist (Wiese et al., 2007). 
In addition to GPCR ligands, zinc has been reported to activate TrkB receptors and its 
downstream signaling pathways in a BDNF independent manner (Huang et al., 2008). 
In contrast to GPCR-mediated activation, the zinc-induced TrkB activation occurs 
quickly (in 5 minutes), thus, with similar kinetics as BDNF-induced TrkB activation. 
Interestingly, also reactive oxygen species (ROS) can activate TrkB receptor via an 
intracellular mechanism requiring zinc (Huang and McNamara, 2012). Zinc can enter 
the cell via the ionotropic NMDA-receptors and activate the Src family kinases similarly 
to other transactivators. Zinc was also shown to increase LTP of mossy fiber-CA3 
synapses via transactivation of TrkB receptors. However, later a study from the same 
group failed to show that vesicular zinc is required for basal TrkB activation in adult 
mouse brain (Helgager et al., 2014). There is some controversy surrounding the role of 
zinc to transactivate TrkB receptors in cell culture, because it has been suggested that 
TrkB activation by zinc requires rapid processing of proBDNF to BDNF, suggesting that 
TrkB activation is mediated by matrix metalloproteinase -facilitated BDNF cleavage and 
not by transactivation (Hwang et al., 2005).  
In addition to GPCR ligands and zinc, low-density lipoprotein receptor-related protein 1 
(LRP1) agonists transactivate TrkB receptors in PC12 cells quickly (10 minutes) (Shi et 
al., 2009). Src family kinases were required also for the LRP1-induction of TrkB 
activation. 
During embryonic development, TrkB transactivation has been shown to regulate the 
migration of cortical precursor cells and developing interneurons (Berghuis et al., 2005; 
Puehringer et al., 2013). At an early embryonic stage (E11) TrkB receptors in cortical 
precursor cells do not respond to BDNF stimulation but instead are activated by 
epidermal growth factor (EGF) (Puehringer et al., 2013). At this developmental 
timepoint the TrkB receptors are located mainly intracellularly and cannot be activated 
by BDNF. However, EGF can transactivate an intracellular pool of Trk receptors that can 
then subsequently be inserted to the cell membrane. Trk receptor transactivation by EGF 
is required for the proper migration of the cortical precursor cells, but does not affect the 
survival of the cells (Puehringer et al., 2013). TrkB also regulates the migration of 
interneurons via transactivation by endocannabinoid anandamide (Berghuis et al., 
2005). TrkB transactivation by EGF and anandamide occurs much faster than the 
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adenosine or PACAP induced transactivation, but Src family kinases are essential for the 
transactivation in all the experiments.  
Interestingly, transactivation of Trk receptors seems to induce a strong phosphorylation 
of a different form of Trk receptors of 110 kDa in size in addition to the normal 145 kDa 
protein and the regulation of this protein can occur even faster than that of the full-length 
form (Lee and Chao, 2001; Lee et al., 2002; Rajagopal et al., 2004). The transactivation 
has been shown to preferentially activate intracellular Trk receptors (Rajagopal et al., 
2004). Because transactivation occurs intracellularly, immaturely glycosylated Trk 
receptors in trans-golgi can be phosphorylated to produce the phosphorylated 110 kDa 
protein (Rajagopal et al., 2004; Schecterson and Bothwell, 2010). In fact, treatment with 
Brefeldin A, an inhibitor of protein transport from endoplasmic reticulum to Golgi 
apparatus, increased the amount of 110 kDa protein  (Rajagopal et al., 2004). 
Interestingly PACAP-induced TrkB transactivation resulted in reversible Golgi 
fragmentation (Schecterson et al., 2010). It is not clear what the consequences of the 
Golgi fragmentation induced by TrkB transactivation are, however, it is hypothesized 
that it could lead to redistribution of Golgi fragments to the dendrites and affect post-
translational processing of dendrite targeted mRNAs. On the other hand, Golgi 
fragmentation can play a role in the pathophysiology of neurodegenerative disorders, 
thus suggesting that it may be harmful (Schecterson et al., 2010). 
It has been suggested that TrkB receptors are expressed as dimers intracellularly before 
ligand binding, which could facilitate transactivation (Shen and Maruyama, 2012). In 
addition to transactivation ligand independent TrkB activation can be experimentally 
achieved with light stimulation using genetically modified TrkB receptors that have a 
light-activatable domain inserted into the intracellular domain (Chang et al., 2014). 
Light-induced TrkB dimerization and activation led to activation of the ERK signaling 
and increase in neurite outgrowth. 
2.1.11 ProBDNF and p75NTR signaling 
In addition to Trk receptors all neurotrophins bind to and activate the p75NTR  
(Rodriguez-Tébar et al., 1990, 1992). As discussed in preceding chapters these two 
receptors can have synergistic, distinct or even opposite effects on neuronal function. 
The p75NTR receptor belongs to the tumor necrosis factor receptor family and can interact 
with multiple co-receptors and depending on the interaction partner initiate signaling 
via different signaling pathways (Dechant and Barde, 2002). P75NTR has been shown to 
increase the specificity and the sensitivity of the Trk receptors to neurotrophins (Bibel et 
al., 1999; Davies et al., 1993). Upon neurotrophin binding p75NTR can inactivate RhoA 
resulting in neurite growth. Some factors, such as NOGO, however, can promote the 
interaction between p75NTR and Rho-GDI leading to increased RhoA activity and 
inhibition of neurite growth (Yamashita and Tohyama, 2003). Moreover, neurotrophin 
binding to p75NTR in the absence of the Trk receptors can induce neuronal death via 
activation of JUN kinase (Bamji et al., 1998; Friedman, 2000).  
Most importantly, proneurotrophins bind to p75NTR with much higher affinity than 
mature neurotrophins (Lee et al., 2001b). Indeed, proBDNF, but not mature BDNF, can 
activate apoptotic signaling in the neurons via binding to a preformed complex of p75NTR 
and sortilin (Nykjaer et al., 2004; Teng et al., 2005). Activation of survival signaling via 
Trk receptor, however, can rescue the cells from the apoptosis in a competitive manner. 
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Thus, pro and mature neurotrophins are able to elicit completely opposing functions and 
the cleavage of neurotrophins importantly determines the effects that follow the release 
of neurotrophins. Naturally, the signaling effects of proneurotrophins require that they 
have to be secreted and not cleaved extracellularly. However, it is still not certain to 
which extent proBDNF is released in vivo.  
In Xenopus nerve-muscle co-cultures the activity-dependent increase in the cleavage of 
proBDNF to BDNF supports the establishment of the active synapse via TrkB and p75NTR, 
while in the non-active synapse proBDNF stimulates the retraction of the synaptic 
terminal (Je et al., 2012). Similar results were obtained from in vivo experiments using 
mouse neuromuscular junctions, namely that proBDNF promotes the synapse 
elimination through p75NTR and sortilin and  mature BDNF supports the survival of the 
synapses via TrkB (Je et al., 2013). Synaptic depression is important in the excitatory 
neuron synaptic clustering, which is considered to be involved in the regulation of 
computational power of the neuron. ProBDNF signaling via the p75NTR mediates the 
decreased transmission of synapses that are active in an asynchronous manner 
compared to their neighboring synapses (Winnubst et al., 2015).  
The role of proBDNF cleavage to BDNF has been studied also in electrophysiological 
experiments. Pang et al. (2004) demonstrated that the cleavage of proBDNF to BDNF 
after secretion is required for the late phase LTP (L-LTP) in hippocampal slices. The 
levels of hippocampal proBDNF in tPA or plasminogen knock out mice are increased 
indicating that these enzymes are involved in the processing of proBDNF. Indeed, tPA 
and plasminogen deficient mice show impaired LTP that can be rescued by application 
of exogenous BDNF (Pang et al. 2004). The cleavage of proBDNF by plasmin is 
important for the LTP since cleavage resistant proBDNF cannot rescue LTP in 
plasminogen or tPA deficient mice. ProBDNF itself had no effect on LTP, however, it 
enhanced LTD. Later it was shown that the facilitation of the LTD by proBDNF depends 
on the p75NTR (Woo et al., 2005). High frequency stimulation (HFS) is required for LTP 
and in hippocampal neuronal cultures it has been shown that HFS results in release of 
tPA together with BDNF/proBDNF (Nagappan et al., 2009). In the presence of tPA more 
mBDNF is formed, which is important for the L-LTP. In contrast low frequency 
stimulation (required for LTD) increases the extracellular ratio of proBDNF to BDNF 
since it does not increase secretion of tPA. Thus, the extracellular cleavage of proBDNF 
to BDNF determines also postsynaptic effects of BDNF.   
In BDNF conditional knockout mice the LTD was not affected in hippocampal slices (but 
LTP was impaired), suggesting that proBDNF is not necessary for LTD (Matsumoto et 
al. 2008). In p75NTR knockout mice, however, especially the NMDA receptor-dependent 
LTD was impaired (Woo et al., 2005). Also mice expressing proconvertase/furin 
cleavage-resistant proBDNF have decreased dendritic complexity in the hippocampus, 
impaired theta burst stimulation-induced LTP and enhanced LTD in Schaffer collaterals  
(Yang et al., 2014).  
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2.2 Role of BDNF and TrkB in CNS development and function 
2.2.1 Cell survival and differentiation 
The neurotrophins are essential for the development of the nervous system, and are 
known to regulate physiological functions also in the adulthood. During development 
neurotrophins are required to support the survival of a limited number of neurons that 
compete for target innervation. This applies mostly to the PNS and has been extensively 
studied in relation to survival of peripheral neurons. The applicability of the 
neurotrophin hypothesis to the CNS has not been reliably proven but according to 
current data it does appear to apply to certain populations of neurons. Notably, 
significant proportion of CNS neurons also undergoes apoptosis during early 
development. An interesting finding suffests that in contrast to TrkA and TrkC receptors 
TrkB receptor does not seem to be a dependence receptor that would induce apoptosis 
in the absence of ligand (Nikoletopoulou et al., 2010).  
In general, neurons of the PNS are more dependent on certain neurotrophin and/or 
certain neurotrophin receptor compared to neurons in the CNS. Mice with complete 
deletion of BDNF or TrkB do not survive after birth because of deficits in peripheral 
nervous system innervation (Ernfors et al., 1994; Klein et al., 1993). Specific deficits in 
the nodose-petrosal ganglion, which brings gastrointestinal, cardiac and respiratory 
information to the CNS, results in problems with breathing and cardiac function that 
may underlie the fatal phenotype of the BDNF and TrkB knockout mice (Conover et al., 
1995; Erickson et al., 1996; Jones et al., 1994; Silos-Santiago et al., 1997). TrkB knockout 
mice also have reduced amounts of vestibular neurons and loss of semicircular canal 
innervation causing defects in balance. TrkB or BDNF deletion does not cause gross 
deficits in the CNS, but decreases the amount of interneuron markers suggesting that 
BDNF-TrkB signaling is specifically involved in interneuron maturation and function 
(Alcántara et al., 1997). Parvalbumin expression is delayed in the TrkB knockout mouse 
hippocampus and cortex and cell death is increased during the first postnatal weeks 
compared to wild type mice in the cortex, hippocampus (especially dentate gyrus), 
striatum, septum, thalamus and olfactory bulb with specific temporal patterns (striatum 
earlier, dentate gyrus later) (Alcántara et al., 1997; Minichiello and Klein, 1996). Proper 
parvalbumin expression in interneurons and formation of GABAergic inhibitory 
synapses requires BDNF, TrkB and neuronal activity (Patz et al., 2004; Rico et al., 2002). 
BDNF and TrkB are involved in the regulation of dendritic branching, adjusting the 
number of dendritic spines and in synapse formation for example in some neuronal 
populations of the hippocampus and cortical layer 4 (Luikart et al., 2005; Martınez et al., 
1998; McAllister et al., 1995; Xu et al., 2000a). In vivo some striatal neurons require 
BDNF and TrkB for survival during development and for dendritic complexity in 
adulthood (Baydyuk et al., 2011; Rauskolb et al., 2010). Also migration of neurons in the 
developing neocortex is delayed in mice lacking TrkB receptor affecting the stratification 
of the cortex and differentiation of neurons (Medina et al., 2004).  
 The effects of BDNF-TrkB signaling on the differentiation and survival of neurons have 
been mainly studied in vitro. BDNF increases the differentiation of neuronal precursor 
cells and promotes neurite outgrowth and survival of cultured neurons (Ahmed et al., 
1995; Baj et al., 2011; Kirschenbaum and Goldman, 1995; Vicario-Abejón et al., 1998). 
BDNF stimulation also increases the number of excitatory and inhibitory synapses in 
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cultured hippocampal neurons and seems to affect especially the neurite outgrowth of 
GABAergic cells supporting the in vivo findings that BDNF is required for the normal 
development of inhibitory interneurons. Reduction in markers for GABAergic synapses 
could also be found when TrkB kinase function was inhibited for 20 days suggesting that 
the maintenance of the GABAergic synapses requires TrkB signaling also during 
adulthood (Chen et al., 2011). Signaling via the PLCγ binding site of the TrkB receptor 
seems to be important for these effects. 
2.2.2 Plasticity 
The interest to the possible plasticity promoting effects of neurotrophins were raised by 
the findings that seizure activity and sensory stimulation led to increased expression of 
neurotrophins (Thoenen, 1995). Neuronal plasticity is the ability of the brain to change 
in response to experience, environment and intrinsic activity. The processes regulating 
brain plasticity on a molecular or structural level involve the strengthening or weakening 
of synapses and the formation or elimination of synaptic connections. Experimental 
approaches to elucidate plasticity include analysis of neurogenesis, dendritic spines and 
long-term potentiation. 
Neurogenesis 
Formation of new neurons and their integration into existing neural networks is an 
important mechanism of neuronal plasticity. Neurogenesis in the adult brain was a 
matter of debate for decades but now it is well accepted that adult neurogenesis takes 
place in the subventricular zone (SVZ) of lateral ventricles and subgranular zone (SGZ) 
of dentate gyrus (Zhao et al., 2008). Mice that lack BDNF have increased apoptosis 
around the subventricular zone and in the dentate gyrus after the first two postnatal 
weeks (Linnarsson et al., 2000). Voluntary exercise on a running wheel or an enriched 
environment are well-known means to enhance neurogenesis in laboratory animals 
(Zhao et al., 2008). The main factors that are known to negatively affect neurogenesis 
are stress (glucocorticoids) and aging.  
In dentate gyrus SGZ there are neural progenitor cells that continue to divide also in the 
adult brain producing neurons that migrate to the granule cell layer and extend dendrites 
to the molecular layer and axons to the CA3 region (van Praag et al., 2002). The basal 
level of bromodeoxyuridine (BrdU) -labeled adult-born neurons is normal in BDNF 
conditional knockout mice (BrdU incorporates into newly synthesized DNA), however, 
following environmental enrichment and voluntary exercise the amount of BrdU labeled 
cells increased more in the hippocampus of wild type mice compared to BDNF 
conditional knockout mice (Choi et al., 2009). BDNF deletion affected the survival of 
adult-born neurons, resulting in significantly reduced levels of BrdU-labeled cells 
measured 4 weeks after the BrdU injection when the mice were housed in a standard or 
enriched environmental conditions. BDNF heterozygous knockout mice also show 
reduced survival of hippocampal new-born neurons after environmental enrichment or 
chronic antidepressant treatment (Rossi et al., 2006; Sairanen et al., 2005). 
Intrahippocampal infusion of BDNF increased the amount of new-born neurons, but 
unexpectedly more in the contralateral side of the infusion, suggesting that BDNF does 
not directly affect these cells since BDNF presumably does not diffuse widely from the 
injection site (Scharfman et al., 2005).  
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Type B and ependymal cells in the SVZ express high levels of TrkB and low levels of 
BDNF (Galvão et al., 2008). The TrkB receptor expressed in SVZ is, however, mainly the 
truncated form of the receptor (TrkB.T1). TrkB expression co-localized with BrdU 
suggesting that stem cells of the SVZ express TrkB (Galvão et al., 2008). When the stem 
cells from TrkB knockout mice were grafted to adult wild type mice they did not show 
any difference when compared to grafts from wild type mice in regards to their ability to 
give rise to new neurons or in the migration or differentiation of the olfactory bulb 
neurons; suggesting that TrkB-mediated signaling is not critical for these effects (Galvão 
et al., 2008). However, similarly to hippocampus, TrkB signaling may be necessary for 
the maturation or survival of the cells in SVZ.  
Intraventricular administration of BDNF has been reported to increase the amount of 
BrdU labeled olfactory bulb neurons in the adult rat brain (Benraiss et al., 2001; Zigova 
et al., 1998). However, an osmotic minipump releasing BDNF for 14 days to the lateral 
ventricle had no effect on the amount of new cells in the olfactory bulb of mice and, in 
fact, decreased the BrdU-labeled cells in the olfactory bulb of rats likely due to decreased 
proliferation of SVZ cells (Galvão et al., 2008). Infection of anterior SVZ cells with 
BDNF-expressing virus increased proliferation and/or survival of neural progenitor cells 
(Henry et al., 2007). Also in both of these studies increased BrdU-labeling was noticed 
in the striatum. Striatal neurogenesis has not been fully observed in the adult brain, yet, 
from human studies there is some evidence that new neurons can be found in adult 
striatum (Ernst et al., 2014). Damage to some brain areas can result in increased 
neurogenesis, and BDNF has been shown to have controversial effects in these situations. 
In a study by Henry et al. (2007) BDNF increased the amount of BrdU positive cells in 
chemically lesioned striatum. In another study, however, long-term hippocampal viral 
expression of BDNF in dentate gyrus prevented the formation of new-born after ischemic 
injury (Larsson et al., 2002).  
Long-term potentiation 
Long-term potentiation, LTP, is a persistent increase in the synaptic strength induced by 
brief high frequency electrical stimulation or coincident activation of pre- and 
postsynaptic neurons (Minichiello, 2009).  LTP is considered as a cellular mechanism 
underlying learning and memory. 
Application of BDNF directly to hippocampal slices enhances synaptic strength in the 
Schaffer collateral-CA1 synapse in a TrkB-dependent manner (Kang and Schuman, 
1995). In contrast, LTP in Schaffer collaterals is impaired in BDNF heterozygous 
knockout mice (Korte et al., 1995). However, BDNF knockout and BDNF heterozygous 
knockout mice had similar impairments in LTP, with LTP being induced in some slices 
also in the absence of BDNF, indicating that in all conditions normal levels of BDNF are 
not necessary for LTP. Viral expression of BDNF in CA1 neurons or application of 
recombinant BDNF can mostly rescue impaired LTP, suggesting that BDNF itself is 
required for LTP and the deficits are not caused by abnormalities due to the lack of BDNF 
during the development (Korte et al., 1995; Patterson et al., 1996). The late-phase LTP in 
particular seemed to be affected in the absence of BDNF (Korte et al., 1996). Activation 
of presynaptic NMDA receptors by neuronal activity results in increased intracellular 
calcium concentration that triggers the release of BDNF from presynaptic terminals 
(Park et al., 2014).  BDNF is released from the presynaptic neurons presumably together 
with glutamate to induce LTP and in this manner seems to specifically potentiate the 
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highly active synapses (Gottschalk et al., 1998; Zakharenko et al., 2003). This is further 
supported by the finding that application of BDNF to dendrites, but not to axons, evoked 
a calcium response and induced LTP when combined with brief electrical stimulation 
(Kovalchuk et al., 2002). Long-term spine enlargement related to LTP requires that 
BDNF is secreted specifically in the active synapses (Tanaka et al., 2008). BDNF 
promotes spine enlargement via activation of cofilin and p21 activated kinase that are 
involved in regulation of spine morphogenesis (Rex et al., 2007). 
The effects of BDNF on LTP are mediated through TrkB receptor and requires especially 
the signaling initiated by PLCγ binding to Y816 of TrkB (Minichiello et al., 2002). In 
addition to experiments using slices, the impairment of LTP in mice with point mutation 
in TrkB PLCγ binding site was also demonstrated by in vivo electrophysiological 
recordings (Gruart et al., 2007). It has also been suggested that BDNF-induced activation 
of presynaptic TrkB receptors is required for LTP (Xu et al., 2000b). To support the 
requirement for both presynaptic and postsynaptic TrkB, intact presynaptic and 
postsynaptic PLCγ signaling is required for hippocampal LTP (Gärtner et al., 2006). 
Interestingly, mice overexpressing TrkB show increased PLCγ activation and enhanced 
spatial learning but impaired LTP (Koponen et al., 2004). It was suggested that the 
baseline synaptic activity in these mice is enhanced, which could lead to occlusion of LTP.  
BDNF-TrkB in visual cortex plasticity 
Basic organization of the brain occurs during early development independently of 
external stimuli. Molecular factors defined by genetics and intrinsic activity in the brain 
result in the formation of basic neuronal networks (Levelt and Hübener, 2012). A critical 
period is a well-defined time window during which environmental sensory stimulus is 
required for proper wiring and fine-tuning of neuronal networks in the brain. During the 
critical period the sensory stimulus, or lack there of, permanently affects the network in 
question. Sensory stimuli have less impact on the neuronal wiring before and after the 
critical period. In addition to sensory systems, it has been suggested that critical period 
exists in fear extinction (Gogolla et al., 2009). The molecular mechanisms of critical 
periods have been extensively studied and understanding how to enhance plasticity of 
the adult brain could be beneficial in the treatment of psychiatric disorders, which often 
have a developmental origin possibly caused by abnormal critical period and are difficult 
to treat when symptoms appear in adulthood.   
Visual cortex is a generally-used model for studying critical period plasticity in the rodent 
brain. During the critical period of binocular vision formation the local inhibitory 
neurons in the primary visual cortex mature (Hensch, 2005).  During the critical period 
it is possible to permanently alter the physical microstructure and organization of the 
visual cortex that may result in amblyopia. Apparently the columnar organization of the 
ocular dominance columns is well-established before the critical period but the sensory 
nformation during the critical period is able to modify the size of the columns and 
individualize the ocular dominance maps (Hensch, 2005). 
Axons projecting from the lateral geniculate nucleus of the thalamus form eye-specific 
ocular dominance columns in the layer IV of the visual cortex during development 
(Cabelli et al., 1995). BDNF expression is not necessary for the formation of the eye-
specific columns (Lyckman et al., 2005), however, infusion of TrkB-IgG, which binds to 
BDNF and possible other TrkB-binding molecules, can block the formation of the ocular 
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dominance columns suggesting that BDNF together with other endogenous TrkB ligands 
mediate this effect (Cabelli et al., 1997). Interestingly, BDNF infusion to the visual cortex 
can prevent the ocular dominance column formation by possibly disturbing activity-
dependent competition of target innervation.  
Visual input and light exposure regulates bdnf mRNA expression in the visual cortex 
(Castrén et al., 1992). If adult rats are kept in total darkness for one week bdnf mRNA 
expression in the visual cortex is reduced but can be restored quickly by one hour 
exposure to light. Also the normally occurring reduction in the sizes of receptive fields 
and improvement of visual acuity is impaired if rats are reared in darkness from birth 
(Fagiolini et al., 1994). In transgenic mice overexpressing BDNF in CaMKII-positive 
neurons the reduction in visual acuity by dark rearing is prevented (Gianfranceschi et al., 
2003). Interestingly, visual experience is not required for visual acuity in these mice. 
Also, the receptive fields of dark-reared BDNF-overexpressing mice were not increased 
similarly to dark-reared wild type mice. Dark rearing in wild type mice prolonged the 
critical period so that monocular deprivation at P40 still produced a shift in ocular 
dominance. In BDNF-overexpressing mice the critical period for visual cortex occurs and 
closes earlier in development than in wild type mice and it cannot be delayed by dark 
rearing (Gianfranceschi et al., 2003; Hanover et al., 1999; Huang et al., 1999). BDNF-
overexpressing mice show faster maturation of inhibitory interneurons, e.g. parvalbumin 
neurons, in the visual cortex (Huang et al., 1999). In contrast, dark rearing delays the 
emergence of GABAergic inhibition in the visual cortex in wild type mice, whereas BDNF 
overexpression allows for normal emergence of the GABAergic inhibition in the dark-
reared animals (Gianfranceschi et al., 2003). Reduced BDNF levels do not seem to affect 
the critical period of the visual system, since BDNF heterozygous knockout mice have 
normal critical period (Bartoletti et al., 2002).  
2.2.3 BDNF and TrkB mutations and polymorphisms in humans 
Information about the role of BDNF and TrkB in humans has been obtained from 
patients with genetic mutations in the bdnf and trkb genes. Patients with a rare genetic 
disorder, WAGR syndrome, have a chromosomal deletion that in some cases includes the 
whole bdnf gene. Patients with heterozygous bdnf deletion show hyperphagia (increased 
appetite) and impaired pain sensation and have a higher body mass index (BMI) than 
WAGR patients without bdnf deletion (Han et al., 2008). In the patients with bdnf 
deletion also the serum BDNF levels were about 50 % lower. In addition, impaired 
adaptive behavior, cognitive function and speech and language skills were linked to the 
bdnf deficiency (Han et al., 2013; Shinawi et al., 2011). Patients with WAGR syndrome 
may have deletions of large numbers of genes, making it difficult to distinguish the effects 
of only bdnf deletion. However, symptoms of subjects without WAGR syndrome who 
have bdnf deletions support these findings, since the subjects were obese,  insensitive to 
pain and had neurodevelopmental and behavioral phenotypes (Ernst et al., 2012). 
Moreover, in a case study a patient with bdnf haploinsufficiency was obese, hyperactive, 
developmentally delayed especially in speech and language skills, and manifested 
decreased sensitivity to pain, low IQ, impaired attention and short-term memory 
function (Gray et al., 2006). 
De novo loss-of-function mutation in TrkB gene was found in an 8-year old boy suffering 
from severe obesity and hyperphagia (Yeo et al., 2004). In addition, the boy had 
developmental delay especially in speech and language, deficits in short-term memory, 
23 
 
stereotypic behavior and impaired nociception. The mutation resulted in replacement of 
one tyrosine residue by cysteine in the catalytic domain of the receptor. When studied in 
cell culture (PC12 cells) this mutation seemed to decrease the ligand induced 
phosphorylation of the receptor and also impaired downstream ERK phosphorylation. 
The bdnf haploinsufficient patient basically shows similar phenotypes as the patient with 
the loss-of-function mutation in the trkb gene. 
An interesting polymorphism in the bdnf gene results from a single amino acid 
substitution of valine to methionine in the prodomain of BDNF at codon 66 (BDNF 
val66met) (Egan et al., 2003). BDNF met polymorph impairs the episodic memory in 
humans. BDNF met polymorphism, however, does not seem to be a risk factor for 
depression in humans (Verhagen et al., 2010). In contrast to BDNF haploinsufficiency, 
BDNF val66met polymorphism was not associated with obesity or eating disorders 
(Friedel et al., 2005). The substitution does not occur in mature BDNF but in the pro-
domain of proBDNF, thus, it does not seem to have a direct effect on the functions of the 
mature BDNF, for example on the activation of the TrkB receptor or on the ability of 
BDNF to induce neurite outgrowth in PC12 cells (Egan et al., 2003). However, this single 
amino acid substitution seems to affect the intracellular processing and activity-
dependent secretion of BDNF. 
It has been estimated that 20-30 % of human population is heterozygous for the BDNF 
val/met, which means that both Val- and Met-form of BDNF can be expressed. When co-
expressed val- and met-BDNF can form heterodimers affecting the distribution of the 
val-BDNF in the cell that results in its increased accumulation in the cell body because 
of abnormal sorting from Golgi apparatus to the secretory granules in PC12 cells (Chen 
et al., 2004). 
In a fear conditioning paradigm human BDNF met allele carriers did not differ from 
val/val carriers (Soliman et al., 2010). However, the met allele resulted in impaired fear 
extinction that was accompanied by decreased activity in the ventromedial prefrontal 
cortex and increased activity of the amygdala in human neuroimaging studies done 
during extinction training. In another human imaging study the met allele was associated 
with slightly impaired memory retrieval (Hariri et al., 2003). Hippocampal activity was 
reduced in subjects with the met allele during memory encoding and retrieval, however, 
it has been found that hippocampal volume of the met allele carriers is decreased (Hajek 
et al., 2012). 
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2.3 NEUROTROPHIN AND NETWORK THEORIES OF ANTIDEPRESSANT ACTION 
2.3.1 Antidepressant drugs  
The first antidepressant drugs (AD) were serendipitously discovered in the 1950’s. The 
monoamine oxidase (MAO) inhibitor iproniazid was tested for treatment of tuberculosis 
but was found to improve the mood of depressed patients receiving the medicine 
(Castrén, 2005). Iproniazid was soon followed by the first tricyclic antidepressant 
imipramine. Because both of these drugs affect the monoamine neurotransmitters it was 
suggested that depression may be caused by abnormal levels of monoamines that could 
be normalized with antidepressant treatment (Schildkraut, 1965). MAO inhibitors and 
tricyclic antidepressants were followed by more selective drugs targeting noradrenergic 
or serotonergic systems, for example the selective serotonin reuptake inhibitors (SSRI) 
that are widely used today.  
In general, antidepressant drugs require weeks of treatment before their therapeutic 
effects appear. The primary pharmacological effects of the drugs on monoamines appear 
almost immediately suggesting that the therapeutic effects of ADs are not directly 
evolving from the increased monoamine levels in the synaptic cleft.  Adaptation and 
plasticity of the neuronal networks resulting from chronic exposure to ADs could 
underlie the slow manifestation of the clinical therapeutic effect of ADs (Castrén, 2013). 
It is also interesting that monoamine depletion, which leads to a lack of serotonin or 
noradrenaline/dopamine in the brain, cannot produce depressive-like symptoms in 
healthy volunteers and does not lower mood in depressed patients (Ruhé et al. 2007).  
This suggests that there is no direct correlation with the brain monoamine levels and the 
depressed mood. However, the depletion in experimental conditions is acute and it is 
possible that longer depletion is required to induce depression symptoms. In subjects 
who had been previously treated with antidepressant drugs but are in a remission, 
tryptophan depletion moderately decreased the mood whereas phenylalanine/tyrosine 
depletion had no significant effect (Ruhé et al., 2007). In patients, who are in remission 
and are currently treated with antidepressant drugs, depletion of the corresponding 
monoamine in which the drug exerts its main effect can reinstate the depressive 
symptoms (e.g. tryptophan depletion in patients using SSRIs) (Ruhé et al., 2007). These 
results suggest that depressed patients are more susceptible to depressive symptoms 
because of a possible vulnerability in their monoaminergic systems. Interestingly, in 
healthy volunteers with a family history of major depressive disorder a slight reduction 
in the mood could be achieved with monoamine depletion, suggesting a genetic 
component involved in the sensitivity to the effects of monoamine depletion (Ruhé et al., 
2007). 
2.3.2 Concept of neurotrophin theory of depression and antidepressant action 
Neurotrophin theory of depression postulates that reduction of BDNF expression would 
impair the survival and connectivity of neurons resulting in neuronal atrophy, especially 
in brain areas vulnerable to stress and involved in the regulation of mood (e.g. 
hippocampus) (Duman et al., 1997). The expression levels of BDNF may be promoted 
following treatment with antidepressant drugs aiding the neurons in resisting the 
negative effects of stress to restore connectivity. In support of the neurotrophin theory 
of depression, reduced BDNF levels in the brain and serum of depressed patients, as well 
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as increases in BDNF expression after AD treatment has been reported (Chen et al., 2001; 
Karege et al., 2002, 2005; Matrisciano et al., 2009; Shimizu et al., 2003).  
In the blood BDNF is found in the platelets and it can be released upon stimulation 
induced by stress or injury (Fujimura et al., 2002). Megakaryocytes, which produce the 
platelets, express bdnf mRNA in humans and rats but not mice (Chacón-Fernández et 
al., 2016). Megakaryocytes also store BDNF protein, which is then transferred to 
platelets. Levels of BDNF in serum from depressed patients are found to be lower 
compared to healthy controls, with some studies suggesting that BDNF levels are 
correlated with the severity of depressive-like symptoms (Karege et al., 2002, 2005; 
Pandey et al., 2010). Antidepressants appear to increase BDNF levels in serum since 
depressed patients treated with ADs have elevated levels of BDNF in serum compared to 
non-treated controls, however, the ability of different ADs to affect BDNF levels seem to 
vary (Matrisciano et al., 2009; Shimizu et al., 2003). In support of these findings, in 
meta-analyses BDNF concentration has been found to be lower in the serum of depressed 
patients than in healthy controls or antidepressant-treated depressive patients, however, 
no correlation between BDNF levels and symptom severity was found (Molendijk et al., 
2014; Sen et al., 2008). Low serum BDNF concentration is thought to result from 
decreased release of BDNF from the platelets and not from the overall decrease in blood 
BDNF levels (Karege et al., 2005).  
In addition to blood, changes in brain BDNF levels have been observed in post mortem 
studies of depressed patients. Specifically, patients on antidepressant medication have 
increased BDNF expression in the hippocampus, whereas suicide victims have reduced 
BDNF and TrkB expression in the hippocampus and prefrontal cortex (Chen et al., 2001; 
Dwivedi et al., 2003) 
2.3.3 Regulation of BDNF and TrkB by stress and antidepressant drugs 
The neurotrophin hypothesis of depression is supported by animal studies. Stress and 
glucocorticoid injections were first shown to downregulate bdnf mRNA expression in the 
hippocampus (Smith et al., 1995a). Stress did not produce changes in cortical bdnf levels 
and, in fact increased bdnf expression in the hypothalamus and pituitary gland (Smith et 
al., 1995b). The length, timing, and type of stressor affect bdnf expression in a 
complicated manner since some bdnf transcripts are downregulated and some 
upregulated in specific hippocampal subfields (Nair et al., 2006). Stress-induced 
downregulation of bdnf in the hippocampus could be prevented by chronic 
antidepressant treatment, electroconvulsive shocks or voluntary exercise (Dwivedi et al., 
2006; Nibuya et al., 1995a; Russo-Neustadt et al., 2001). Chronic AD treatment per se 
also increased bdnf and trkb mRNA levels in the hippocampus and the frontal cortex. 
The combination of an antidepressant drug and voluntary exercise increased 
hippocampal bdnf expression even more than either treatment alone (Russo-Neustadt et 
al., 2001). Chronic antidepressant treatments can also prevent the increase in the 
immobility time in the forced swim test (FST) and reduction in the sucrose consumption 
in the sucrose preference test that can be seen in rodents after chronic stress (Haenisch 
et al., 2009). 
Important finding linking BDNF and mood came from studies showing that BDNF could 
modulate monoaminergic systems that have been strongly related to depression 
(Mamounas et al., 1995; Siuciak et al., 1996). It was demonstrated that BDNF infusion 
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for 6-7 days into the midbrain produced antidepressant-like behavior in the  learned 
helplessness model and the forced swim test in rats; suggesting that BDNF itself was 
sufficient to induce antidepressant-like behavioral responses (Siuciak et al., 1997). 
Injection of BDNF into the dentate gyrus or CA3 of the hippocampus, or 
intracerebroventricular infusion of BDNF also resulted in AD-like behavior in rats 
(Hoshaw et al., 2005; Shirayama et al., 2002). Intrahippocampal implant releasing 
BDNF during 2 days reduced immobility in the FST when tested 7 days after 
implantation (Sirianni et al., 2010). BDNF overexpression in the dorsal dentate gyrus 
prevented the reduction in sucrose preference after chronic mild stress paradigm 
suggesting that BDNF could increase the resilience to stress (Taliaz et al., 2011).  
The antidepressant-like effects of BDNF are likely mediated via its receptor TrkB and it 
has been demonstrated that mice overexpressing TrkB show antidepressant-like 
behavior in FST (Koponen et al., 2005). TrkB overexpressing mice have increased 
baseline activation of the receptor, which could explain the behavioral phenotype. 
Supporting this idea, intact BDNF-TrkB signaling is necessary for the behavioral effects 
of antidepressant drugs in the FST since BDNF heterozygous knockout mice, BDNF 
conditional knockout mice, and mice overexpressing the truncated isoform of the TrkB 
receptor do not respond normally to antidepressant drugs (Monteggia et al., 2004; 
Saarelainen et al., 2003). Antidepressant drugs with unique pharmacological profiles 
activate TrkB receptors and signaling pathways in the mouse brain (Rantamäki et al., 
2007; Saarelainen et al., 2003). Whether ADs activate TrkB through increasing the 
release of BDNF or through other mechanisms remains to be investigated. 
An often cited paper from Eisch et al. 2003 describes that infusion of BDNF to ventral 
tegmental area (VTA) shortens the latency to the first immobility period in FST (Eisch et 
al., 2003). However, the number of the rats in the test was really small, only 4-5 animals 
per group and there was no effect of BDNF on the immobility time. Therefore the results 
generated from this paper do not fully demonstrate the role of BDNF in VTA on 
behavioral effects in the FST. It has been later shown that electroconvulsive shock (a 
model of electroconvulsive therapy (ECT)) treatment for 10 days increased BDNF 
expression in the dorsal dentate gyrus but decreased BDNF expression in the ventral 
tegmental area (Taliaz et al., 2013). Knocking down BDNF from the dentate gyrus did 
not, however, abolish the antidepressant-like effect of ECT whereas overexpression of 
BDNF in the VTA could block the behavioral effects of ECT in the FST. BDNF 
overexpression in the VTA reduced sucrose preference and that could be rescued by ECS. 
Additionally, BDNF expression in the VTA has been linked to the development of social 
aversion in the social defeat stress paradigm. Social defeat stress increased BDNF 
expression in the nucleus accumbens and BDNF deletion specifically in VTA (the most 
probable source for BDNF in nucleus accumbens) prevented the defeated mice from 
developing social aversion behavior (Berton et al., 2006). Chronic social defeat stress 
also downregulated bdnf mRNA in the hippocampus affecting especially the 
transcription of bdnf variants III and IV (Tsankova et al., 2006). Chronic treatment with 
AD imipramine prevented the decrease in bdnf mRNA and also increased bdnf mRNA in 
non-stressed mice.  
2.3.4 Neurogenesis and depression  
The first study showing that chronic (14-28 days), but not single treatment with 
antidepressant drugs and electroconvulsive shocks (10 days) increases neurogenesis 
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(proliferation) in the rat brain was done by Malberg et al. (2000). The effect of 
antidepressant drugs was specific to the hippocampus since in the subventricular zone 
antidepressant drugs had no effect on the neurogenesis. Then, Santarelli et al. (2003) 
showed the same effects in mice. X-ray irradiation of the subgranular zone abolished the 
behavioral effect of fluoxetine in the novelty suppressed feeding test and also in some 
parameters measured after chronic unpredictable stress model indicating the 
requirement for neurogenesis in the behavioral effects of fluoxetine. Chronic fluoxetine 
treatment increases proliferation, facilitates the maturation and promotes the survival of 
newborn cells and it can prevent the stress-induced downregulation of hippocampal 
neurogenesis (Alonso et al., 2003; Wang et al., 2008). 
Chronic treatment with fluoxetine increases the amount of BrdU positive neurons in the 
hippocampus while simultaneously activating apoptosis; suggesting that 
antidepressants affect the turnover of newborn cells rather than cell proliferation 
(Sairanen et al. 2005). However, after chronic antidepressant treatment the survival of 
the new-born cells seems to be increased. Antidepressant-induced proliferation in the 
SGZ was unaffected in BDNF heterozygous knockout mice or in mice overexpressing the 
truncated TrkB receptor, suggesting that BDNF-TrkB signaling is not critical for 
regulating the effects of antidepressant drugs on proliferation of neural precursor cells. 
Long-term survival of newborn cells was decreased in BDNF heterozygous knockout 
mice or TrkB.T1 overexpressing mice and the antidepressant effect was abolished.  
There exists a strong correlation between the time course of the neurogenesis and the 
behavioral effects of antidepressant drugs, thus supporting the hypothesis that 
neurogenesis could underlie some important aspects of therapeutic effects of 
antidepressant drugs (Castrén and Hen, 2013). This is further supported by the findings 
from human studies that show an increased expression of neural progenitor cells in the 
dentate gyrus of SSRI treated patients compared to non-treated patients or patients 
treated with tricyclic antidepressant drugs (Boldrini et al., 2009, 2012). Additionally, the 
volume of the dentate gyrus was larger in the SSRI treated patients. In baboon 
hippocampus chronic treatment with antidepressant fluoxetine did not affect the 
proliferation of adult born neurons (Wu et al., 2014). How ADs exactly promote 
neurogenesis is not known. In general the microenvironment around the neural stem 
cells (i.e. the neurogenic niche) can regulate the function of the neural progenitor cells, 
and it is possible that antidepressants promote expression or availability of some critical 
regulators of neurogenesis (Zhao et al. 2008). 
Additional plasticity promoting effects are associated with antidepressant drugs. These 
include increases in dendritic spines of inhibitory interneurons of PFC and pyramidal 
cells of the CA1 and CA3 areas of the hippocampus (Guirado et al., 2014; Hajszan et al., 
2005). Furthermore, antidepressants have been shown to enhance LTP in the medial 
perforant path-dentate gyrus pathway and in the lateral amygdala (Karpova et al., 2011; 
Wang et al., 2008). 
2.3.5 The concept of network theory of depression and antidepressant action 
The delayed onset of action of antidepressant drugs brought about the idea that the 
clinical effects of ADs require adaptation and changes at the neuronal network level 
(Castrén, 2013; Castrén and Hen, 2013). The plasticity of the adult brain is restricted, 
however, the molecular mechanisms of learning and memory are based on brain 
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plasticity that is expressed as strengthening or weakening of synapses. In addition to 
changes in existing synapses, new neuronal connections can be formed when adult born 
neurons connect to existing neural networks indicating adult neurogenesis affects 
neuronal plasticity (Castrén and Hen, 2013). Plastic changes on the structural or 
functional level can eventually result in remodeling of complete neural networks. 
Information processing (e.g. emotions) requires the cooperation of multiple brain 
regions via neural networks (Castrén, 2005). The information transmitted between brain 
areas can be enhanced or diminished as a result of network level plasticity. In depressed 
patients abnormalities in morphology and wiring of the areas involved in emotional 
processing have been detected (Price and Drevets, 2009). It has been reported that 
depressed patients have synaptic atrophy in the dorsolateral PFC and decreased volumes 
of PFC and hippocampus (Kang et al., 2012; Savitz and Drevets, 2009). Depression can 
be a manifestation of these structural and functional changes in the mood-related neural 
networks. Plastic processes involved in the recovery from depression likely affect the 
neural networks controlling mood, balancing their actions to resemble the healthy state 
(Castrén, 2005).  
An important aspect of the network theory of depression and antidepressant action is 
that the shaping of the neuronal networks requires environmental guidance (Castrén, 
2013). The ability of antidepressant drugs to enhance the plasticity of the brain has been 
shown in studies conducted on rat visual cortex and mouse fear processing circuitry 
(Karpova et al., 2011; Maya Vetencourt et al., 2008). Results from both studies 
demonstrate the requirement for environmental guidance to support antidepressant 
effects. 
2.3.6 Plasticity models and antidepressant drug action 
The antidepressant fluoxetine can restore juvenile-like plasticity in the adult rodent 
visual cortex (Maya Vetencourt et al. 2008). This is a crucial finding supporting the 
hypothesis that the effects of ADs could be mediated by enhanced plasticity of the 
neuronal networks. In the study Maya Vetencourt et al. used two models to examine the 
plasticity of the visual cortex: an amblyopia model and monocular deprivation during 
adulthood. In the amblyopia model one eye is closed during the critical period of visual 
system development, thus resulting in ocular dominance of the open eye in the visual 
cortex and reduction in the visual acuity of the closed eye. After the end of the critical 
period the connections and acuity of the closed eye cannot be restored anymore. 
Similarly, if monocular deprivation is done during adulthood, the connections or acuity 
of the closed eye are not weakening since the critical period is over and the state of the 
visual cortex and binocularity are already established (Hensch, 2005). However, after 
chronic fluoxetine treatment it was possible to modify the connections of the visual 
cortex similarly to what could be done during the critical period (Maya Vetencourt et al., 
2008).  
In adulthood closing of one eye during fluoxetine treatment resulted in a similar shift in 
ocular dominance that can be achieved when the eye is closed during the critical period 
(Maya Vetencourt et al., 2008). In the control group, no shift in ocular dominance was 
observed. During eye closing the response evoked by the closed eye in the visual cortex 
was reduced, demonstrating that the shift in ocular dominance happens because the 
connections from the closed eye are weakening and not because the connections from 
the open eye would be strengthening. In addition, when the amblyopic rats were treated 
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with fluoxetine the visual acuity of the closed eye improved to the level of the normal eye, 
however, it was necessary to close the opposite eye to cause the closed eye to recover. 
This is crucial, since it demonstrates the requirement for environmental guidance for the 
effects of fluoxetine. Another possibility is a need arising from the environment that 
requires adaptation of the connections. If the better eye stays open, the animal can 
continue to use it and there is no need to adjust to new situations, but when the better 
eye is closed there is a requirement for the weaker eye to try to adapt. 
The mechanism underlying how chronic fluoxetine treatment could make the cortex 
more plastic was linked to increased expression of BDNF and reduced levels of GABA-
mediated inhibition in the cortex (Maya Vetencourt et al., 2008). These effects are not 
dependent on the shift of the ocular dominance, but rather appear as a result of chronic 
fluoxetine treatment. As mentioned previously, the fluoxetine-induced shift in ocular 
dominance cannot occur without closing of the stronger eye. In the case of monocular 
deprivation during adulthood, the shift in ocular dominance occured because of 
weakening connections from the closed eye and not because of strengthening of 
connections from the open eye (Maya Vetencourt et al., 2008). The functional role of 
BDNF as a neurotrophic factor is to promote synaptic strengthening rather that 
repression, thus there may be many additional mechanisms contributing to the enhanced 
plasticity. BDNF has an important role as a plasticity inducer or enhancer since direct 
administration of BDNF via minipumps to the visual cortex at the same time with 
monocular deprivation resulted in an ocular dominance shift (Maya Vetencourt et al., 
2008). The likely explanation would be that BDNF via TrkB signaling initiates a process 
which renders the synapses in a more plastic state, including the possibility to strengthen 
but also to weaken the synapses. 
The other mechanism suggested by Maya Vetencourt et al. is reduced GABAergic 
inhibition in the cortex. GABAergic neurotransmission is an important regulator of 
cortical plasticity and increases in the inhibitory GABAergic signaling are linked to the 
closure of the critical period (Hensch, 2005). When diazepam (GABAA receptor positive 
allosteric modulator) was infused to the visual cortex during monocular deprivation it 
could prevent the shift in ocular dominance caused by fluoxetine (Maya Vetencourt et 
al., 2008). This suggests that enhanced GABAergic signaling could block the plasticity 
inducing effects of fluoxetine. It would be interesting to know if diazepam could also 
block the effects of intracortical BDNF infusion. 
Chen et al. studied the effects of fluoxetine on dendritic spine dynamics and found that 
fluoxetine treatment, similarly to monocular deprivation alone, increased retraction and 
elongation of the spines but not the total spine number in the visual cortex layer 1 and 
layer 2/3 interneurons (Chen et al., 2011). In combination with monocular deprivation 
fluoxetine increased spine elongations in layer 2/3 during the first two days of monocular 
deprivation. This was faster than in the group treated with monocular deprivation alone 
without fluoxetine, in which the increase in the spine elongation was seen 4-7 days after 
starting the monocular deprivation. The retraction rate, however, was similar in 
monocular deprivation groups with or without fluoxetine. The retraction of spines co-
occurred with reductions in the amount of inhibitory synapses onto excitatory cells, 
suggesting that monocular deprivation reduces the amount of inhibitory synapses onto 
excitatory neurons and could thus decrease the network inhibition. With fluoxetine these 
changes happen more quickly indicating that fluoxetine “primes” the visual cortex for 
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monocular deprivation by potentially affecting plasticity enhancing mechanisms and 
itself reducing the cortical inhibition (Chen et al., 2011). 
The effect of fluoxetine on plasticity was also demonstrated on brain circuits involved in 
the fear processing, proving that the effect is not specific for the visual system only.  In 
Karpova et al. (2011) fear-conditioning was used to study the antidepressant-induced 
plasticity of the fear processing circuitry. In fear conditioning paradigm the animal is 
exposed to unconditioned noxious stimulus (e.g. electric shock) which is combined with 
the conditioned stimulus (e.g. sound) (Maren, 2001). The animal learns quickly that the 
conditioned stimulus predisposes the noxious unconditioned stimulus and detecting the 
conditioned stimulus leads to freezing behavior. This behavioral response can be 
perturbed by exposing the animal to the conditioned stimulus without the unconditioned 
stimulus thereby removing the connection between stimuli. However, fear memory 
cannot normally be completely removed in adult animals since after a certain period of 
time when the animal is again exposed to the conditioned stimulus the fear is renewed 
and the animal freezes again after detecting the conditioned stimulus (Myers and Davis, 
2006). Interestingly, in young animals fear memory can be permanently removed by 
extinction training (Gogolla et al., 2009). This concept was used in the study of Karpova 
et al. (2011) to investigate the potential “rejuvenating” effect of fluoxetine in an area 
different from visual cortex of adult mice. Fluoxetine indeed facilitated permanent fear 
extinction, since the mice treated chronically with fluoxetine showed reduced fear 
renewal and fear reinstatement (Karpova et al., 2011). This was repeated in two different 
experiments where the mice received chronic fluoxetine treatment either before starting 
the fear conditioning paradigm or in a more clinically relevant set up in which the mice 
were treated with fluoxetine after fear acquisition. In vehicle treated animals the fear 
renewal and reinstatement were clearly detectable. 
The effects of fluoxetine were accompanied by a decreased number of parvalbumin 
positive cells surrounded by perineuronal nets in the basolateral amygdala and CA1 area 
of the hippocampus suggesting that some neurons lost the parvalbumin expression, 
which could be considered as a shift toward a more immature state (Karpova et al., 2011). 
Also other markers related to the more immature state of neurons were detected in the 
amygdala, namely reduction in the expression of potassium-chloride cotransporter 2 
(KCC2) and increases in the expression of polysialynated neuronal cell adhesion 
molecule (PSA-NCAM). Long-term potentiation was enhanced in the lateral amygdala of 
fluoxetine treated animals demonstrating increased synaptic plasticity (Karpova et al., 
2011). As in the study by Maya Vetencourt et al. (2008) BDNF was demonstrated to be 
sufficient to induce changes in synaptic plasticity also in this study, since overexpression 
of BDNF in amygdala after extinction training prevented fear renewal similarly to 
chronic fluoxetine treatment. To further support the BDNF’s role in fear extinction, the 
effects of fluoxetine treatment on fear renewal were lacking in BDNF heterozygous 
knockout mice (Karpova et al., 2011).  
Together these two studies by Maya Vetencourt et al. and Karpova et al. demonstrate that 
chronic fluoxetine treatment enhances plasticity in adult rodent brain. In humans the 
possible alterations in brain plasticity by antidepressant drugs are harder to evaluate but 
some studies have been done. The visual cortex has been used also in humans to study 
the effects of chronic antidepressant treatment. Normann et al. (2007) measured visually 
evoked potentials (VEPs) in healthy human subjects and in patients with major 
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depression, both receiving chronic treatment with sertraline. They found that the cortical 
plasticity induced by prolonged visual stimulus measured as early VEPs was enhanced 
in healthy subjects and reduced in depressed patients when compared to healthy 
controls. In the study there was no group of depressed patients without antidepressant 
treatment, so the effect of antidepressant drugs in depressed patients could not be 
demonstrated. According to the results, the ongoing antidepressant treatment could not 
increase the VEPs of the depressed patients to normal levels. Some of the patients in the 
study were also taking benzodiazepines at the same time with antidepressant drugs, but 
the average VEPs were similar in patients with or without benzodiazepines (Normann et 
al., 2007). In the rat study by Maya Vetencourt et al. (2008) the benzodiazepine 
diazepam could prevent the plastic changes in the visual cortex. Also diazepam blocked 
the neurogenesis-inducing effect of chronic fluoxetine treatment (Wu and Castrén, 
2009), thus suggesting that simultaneous use of antidepressants and benzodiazepines 
may be problematic in depressed patients. 
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2.4 RAPID-ACTING ANTIDEPRESSANT DRUGS 
2.4.1 Short history of rapid antidepressant effects 
Induction of seizure activity in the brain was found to relieve symptoms of psychiatric 
patients in the 1930’s. Pharmacologically induced shocks with insulin or pentylentetrazol 
were followed and soon replaced by electrically-induced seizures (Merkl et al., 2009). 
Electroconvulsive therapy (ECT) was found to be a surprisingly effective treatment for 
psychiatric disorders, especially depression. ECT, however, has side effects that include  
severe memory problems, thus restricting its use. The emergence of antidepressant drugs 
reduced the need for ECT and other shock treatments. ECT, however, is still in use and 
is currently the most effective treatment for the patients who do not respond to 
conventional antidepressant drugs or psychotherapy (Greenberg and Kellner, 2005; 
Group, 2003). The mechanism of action of ECT is not known, but it is thought that 
neurotransmitter systems, especially monoamines and GABA are targeted. For example, 
ECT is known to increase expression of neurotrophic factors, neurogenesis, and increase 
hippocampal volume and connectivity (Abbott et al., 2014; Merkl et al., 2009). Amongst 
other things it has been suggested that the post seizure burst suppression is an important 
factor determining the efficacy of ECT (Langer et al., 1985). In general, understanding 
the mechanism of action of ECT would be beneficial in the development of novel rapid 
and effective depression treatments. 
2.4.2 The effects of rapid-acting antidepressant ketamine  
Ketamine is a non-competitive NMDA receptor antagonist generally used as an 
anesthetic. Ketamine acts as an open-channel NMDA receptor blocker inhibiting the ion 
flux through the channel (Sanacora and Schatzberg, 2015). NMDA receptors are widely 
expressed in the brain and can be found almost in all excitatory synapses (Johnson et al. 
2014). NMDA receptor antagonists were found to produce antidepressant-like behavior 
in animal models and it was discovered that conventional antidepressant drugs affect the 
glutamatergic system with NMDA receptor antagonists having effects that resemble 
those of antidepressant drugs (Papp and Moryl, 1994; Skolnick et al., 1996; Trullas and 
Skolnick, 1990). These findings further encouraged the testing of ketamine in depressed 
humans. The antidepressant effect of a subanesthetic dose of intravenous ketamine 
infusion in humans was first characterized by Berman et al. in a small group of depressed 
patients; and the findings have been replicated in several studies (Berman et al., 2000; 
Murrough et al., 2013; Zarate CA et al., 2006). In human patients the antidepressive 
effect of ketamine appears remarkably fast, within a few hours, and the effect of one 
administration normally lasts up to one week (McGirr et al., 2015). Ketamine has a short 
half-life (about 3 hours) so its long-lasting effects cannot be simply explained by “real-
time” NMDA receptor antagonism.  
The finding that noncompetitive NMDA receptor antagonist memantine does not 
produce antidepressant effects in human patients suggests that ketamine has some 
specific properties that underlie its antidepressive efficacy (Smith et al., 2013; Zarate CA 
et al., 2006). The clinical differences in ketamine and memantine could be explained by 
their off-target effects (other than NMDA receptors) or by their effects on distinct 
populations of NMDA receptors (Johnson et al., 2014). In the absence of Mg2+ both 
ketamine and memantine blocked miniature excitatory postsynaptic currents (mEPSCs) 
suggesting that both are able to block NMDA receptor-mediated responses, however, in 
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physiological conditions (in the presence of Mg2+ ) only ketamine blocked mEPSC’s 
(Gideons et al., 2014). The results obtained on other NMDA receptor antagonists in 
animal models also suggest that ketamine has unique mechanisms of action since they 
do not seem to produce as fast and long-lasting effects as ketamine (Autry et al., 2011; 
Maeng et al., 2008). It has been shown, however, that the NR2B subunit of the NMDA 
receptor is crucial in mediating ketamine’s antidepressant-like behavioral effects in 
rodents (Miller et al. 2014). Recently, it was shown that a metabolite of ketamine, 
(2R,6R)-hydroxynorketamine (HNK) can reproduce the behavioral effects of ketamine 
in animal models (Zanos et al., 2016). (2R,6R)-HNK does not bind to NMDA receptors 
but increases AMPA-mediated currents. The behavioral effects of (2R,6R)-HNK can be 
blocked with pretreatment of 2,3- dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-
7-sulfonamide (NBQX) interestingly even when the NBQX is administered 23,5 h after 
(2R,6R)-HNK. This indicates that AMPA receptor-mediated synaptic potentiation could 
be maintaining the antidepressive effects of ketamine. Pre-treatment with NBQX can 
abolish the antidepressant-like effects of ketamine and another NMDA receptor 
antagonist MK-801, but not imipramine, in FST (Autry et al., 2011; Maeng et al., 2008). 
The role of AMPA receptors in regulating the effects of ketamine is further supported by 
the findings that ketamine increases glutamate levels and can thus promote signaling via 
kainate and AMPA receptors. The counterintuitive finding of increased glutamate levels 
in the PFC after injection of a subanesthetic dose of ketamine was first described in rats 
(Moghaddam et al., 1997). The effects of ketamine on glutamate and GABA 
concentrations in the human PFC have also been studied. Increases in GABA and 
glutamate/glutamine levels in the anterior cingulate cortex were found in human studies 
during ketamine infusion, specifically in the first 30 minutes, and soon after ketamine 
infusion (Milak et al., 2015; Rowland et al., 2005; Stone et al., 2012; Taylor et al., 2012). 
If GABA and glutamate levels were measured from occipital cortex of depressed patients 
3 h or 48 h after ketamine infusion changes were no longer detected (Valentine et al., 
2011). In rats 30 mg/kg ketamine increased GABA, glutamate, and glutamine in the 
mPFC 10 minutes after the injection, but not in hippocampus or after ketamine dose of 
80 mg/kg (Chowdhury et al., 2012). With glutamate levels increased and NMDA 
receptors blocked glutamatergic effects are mediated by kainate and AMPA receptors. 
An anesthetic dose of ketamine also increased the extracellular dopamine levels in the 
PFC partially in an AMPA/kainate receptor-dependent manner (Moghaddam et al., 
1997).  
Riluzole is an NMDA receptor blocker and modulator of glutamate release that has been 
shown to increase the expression of AMPA receptors (Dutta et al., 2015). It has been 
hypothesized to be able to prolong or enhance the ketamine’s antidepressant effects and 
to protect against relapse, especially if the mechanisms of antidepressant effects of 
ketamine are increased AMPA-mediated signaling and blockade of NMDA receptors. No 
significant change, however, in the duration of antidepressant effects of ketamine has 
been observed in humans if ketamine infusion has been followed by treatment with 
riluzole (Ibrahim et al., 2012; Mathew et al., 2010). 
Increases in BDNF protein expression and TrkB signaling has been also linked to the 
antidepressant effects of ketamine in rodents (Autry et al., 2011). Autry et al.  (2011) 
found in their study that ketamine (3mg/kg) rapidly increases protein translation via 
dephosphorylation of eukaryotic elongation factor 2 (eEF2). They show that the 
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translation of mBDNF and proBDNF is significantly increased 30 min after 
administration of ketamine or another NMDA-receptor antagonist MK-801. 
Furthermore, they demonstrate that blockers of the eEF2 kinase, which inhibit the 
phosphorylation of eEF2 by the kinase, have similar effect as ketamine in FST and with 
regards to BDNF protein levels. The AD effects of ketamine and eEF2 kinase inhibitor 
were abolished in the inducible BDNF conditional knockout mice in FST, and for 
ketamine also in TrkB conditional knockout mice indicating that BDNF-TrkB signaling 
is involved in the behavioral effects of ketamine (Autry et al., 2011). However, in BDNF 
heterozygous knockout mice ketamine produced an antidepressant-like effect in the FST 
similarly to wild type mice (Lindholm et al., 2012). In rats, acute administration of 
ketamine (15 mg/kg) increased BDNF protein levels in the hippocampus but chronic 
administration of ketamine with the same dose for 14 days did not (Garcia et al., 2008a, 
2008b). Chronic administration of ketamine with 5, 10, or 15 mg/kg doses, however, 
decreased immobility time in FST.  
The effects of ketamine in mice and humans with the BDNF val66met polymorphism 
indicate that the activity-dependent release of BDNF could be important in regulating 
the effects of ketamine. BDNF met/met mice have decreased spine density and spine 
head diameter in the layer V pyramidal cells of PFC and the ketamine-induced increase 
in spine number is abolished in these mice (Liu et al., 2012). BDNF met/met mice did 
not respond to ketamine when tested 24h post-injection (10 mg/kg) in FST. In a study 
by Laje et al. (2012) depressed human patients carrying the met allele (met/met or 
val/met) did not respond to ketamine as effectively as the val/val carriers (24 % 
reduction in the Hamilton depression rating scale scores in met group and 41 % for 
val/val) when measured 210-230 minutes after ketamine infusion (Laje et al., 2012). 
Infusion of BDNF function blocking antibody to the mPFC of rats 30 minutes before 
ketamine administration (10mg/kg) abolished the behavioral effects of ketamine in the 
FST 24 hours after the ketamine treatment (Lepack et al., 2014). Also pretreatment with 
L-type calcium channel blockers nifedipine or verapamil abrogated the effect of ketamine 
in the FST.  
In addition to rodent studies, the effects of ketamine on blood BDNF levels have been 
assessed in humans. After single ketamine infusion the responding patients showed 
higher increase in blood BDNF levels and the BDNF increase correlated with slow wave 
activity in electroencephalography during sleep (Duncan et al., 2013). The authors 
hypothesized that the increased slow wave activity in ketamine responders is a 
consequence of BDNF-induced synaptic strengthening and enhanced plasticity. A 
significant negative correlation between Montgomery-Åsberg depression rating scale 
score and plasma BDNF concentration in ketamine treated patients, but not in patients 
treated with benzodiazepine midazolam, was found when studied 240 min after 
ketamine infusion (Haile et al., 2014). In some studies, however, the BDNF levels were 
not affected by the ketamine treatment (Machado-Vieira et al., 2009). 
It has been demonstrated that ketamine activates the Akt/ERK-mTOR-p70S6kinase 
pathway rapidly and transiently and increases the levels of synaptic proteins in 2 h after 
the administration (Li et al., 2010). Ketamine also rapidly increased (in 24 h) dendritic 
spines in PFC layer V pyramidal neurons and produced antidepressant-like effects 24 h 
after administration in FST, novelty suppressed feeding and learned helplessness 
paradigms. The effects on synaptic proteins, dendritic spines and behavior could be 
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blocked by intracerebroventricular injection of mTOR inhibitor rapamycin, suggesting 
that mTOR signaling is involved in these actions of ketamine. 
In addition to mTOR signaling, glycogen synthase kinase 3 beta (GSK3β)-related 
mechanisms have been implicated in the action of ketamine. Previously, dysregulation 
of GSK3β has been linked to the pathophysiology of depression and the mechanism of 
action of mood stabilizer lithium (Jope and Roh, 2006). Ketamine (10mg/kg) increases 
GSK3β phosphorylation, which results into inhibition of its function, in the hippocampus 
and cortex (Beurel et al., 2011). Interestingly, memantine also has similar effects on 
GSK3β as seen with ketamine. Using transgenic mice with mutations in the inhibitory 
GSK3α/β phosphorylation sites Beurel et al. (2011) were able to demonstrate that in 
these mice the antidepressant-like effects of ketamine in the learned helplessness model 
were abolished. 
The ability of ketamine to affect fast synaptic transmission and activity of neuronal 
circuits could underlie its rapid antidepressant effects. Recently, ketamine-like effects on 
rat behavior in FST and NSF were achieved by optogenetic stimulation of infralimbic 
cortex (Fuchikami et al., 2015). Interestingly, the antidepressant-like effects achieved 
with the optogenetic stimulation of mPFC remained for almost three weeks in FST. The 
optogenetic stimulation also caused increase in the amount of dendritic spines in the 
infralimbic cortex. In addition the effects of ketamine were blocked by infusing the GABA 
agonist muscimol to the infralimbic cortex and direct injection of ketamine to infralimbic 
cortex could produce antidepressant-like behavior in the FST and NSF, however, only at 
certain dose (10 ng) (Fuchikami et al., 2015). These findings support the hypothesis that 
increased activity in a certain population of neurons in PFC resulting from ketamine 
induced disinhibition could underlie the antidepressant-like effects of ketamine. It is 
possible that in the case of low-dose ketamine treatment specifically the fast-spiking and 
tonically active GABAergic interneurons are sensitive to the NMDA receptor blockade by 
ketamine, which then via disinhibition produces glutamate release and neuronal 
excitability in pyramidal neurons. In pyramidal neurons AMPA and kainate receptors 
may mediate the effects of glutamate. Administration of MK-801 (0,1mg/kg) to rats 
reduced the firing rate of the fast-spiking interneurons and increased the firing rate of 
the regular spiking neurons, suggesting that the cortical excitation caused by NMDA 
antagonists results from disinhibition (Homayoun and Moghaddam, 2007). It is 
important to note, however, that blocking the NMDA receptors results in complex 
network effects that differ also along the timescale of the blockade.  
In another recent paper projections from ventral hippocampus to PFC seemed to be 
important for the sustained (1 week) effects of ketamine in the FST (Carreno et al. 2015). 
K252a infusion to ventral hippocampus blunted the effects of ketamine at the 1 week 
timepoint (30 min timepoint results were not studied or shown in the article). Infusion 
of K252a to hippocampus blocks TrkB receptor activation in hippocampus, but how that 
affects the activity of the cells in PFC was not studied (Carreno et al., 2015). This 
demonstrates that Trk receptor activation in the hippocampus by ketamine is important 
for sustained antidepressant effects. Optogenetic inactivation of ventral hippocampus 
during the ketamine administration did not affect swimming behavior 1 week later but 
increased immobility if done during the FST, indicating that ventral hippocampus-PFC 
circuitry seems to be involved in antidepressant-like behavioral effects of ketamine 
(Carreno et al., 2015). There is also some support for ketamine’s effects on hippocampus-
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PFC circuit from human studies since immediately after ketamine infusion the functional 
connectivity between hippocampus and dorsolateral PFC is increased in healthy human 
subjects (Grimm et al., 2015). 
The ketamine infusion can produce hallucinogenic effects and acutely impair verbal 
learning (Murrough et al., 2014). Abusers who have frequently (about 5 times a week) 
used ketamine for long time have decreased hippocampal function when tested on spatial 
navigation tasks, spatial memory tasks and pattern recognition memory tasks (Morgan 
et al., 2010, 2014). Chronic ketamine use can also increase the risk for cystitis and other 
related problems in the urinary tract (Middela and Pearce, 2011; Muetzelfeldt et al., 
2008). The doses used by recreational ketamine users are, however, different than the 
dose of ketamine used in the treatment of depression. The most common side effects 
after ketamine infusion include nausea, visual disturbances and dizziness (Francois et 
al., 2015). 
2.4.3 The effects of other rapid-acting antidepressant drugs 
The concerns about the therapeutic use of ketamine in the treatment of depression 
emerge from the current lack of knowledge about the proper treatment protocol, long-
term effects and dependence and abuse potential of ketamine (Sisti et al., 2014). Thus, 
the potential of other NMDA receptor antagonists and anesthetics in the treatment of 
depression are of interest. Sub-anesthetic doses of nitrous oxide (laughing gas), which 
also acts as NMDA receptor antagonist, has promoted antidepressant-like effects in a 
small pilot study done on treatment resistant depressed patients (Nagele et al., 2015). 
Also NMDA receptor glycine binding site partial agonist GLYX-13 rapidly alleviated 
depression symptoms in depressed patients (Preskorn et al., 2015) 
Before ketamine was tested for treatment of depression, studies about antidepressant 
potential of isoflurane anesthesia were conducted (Langer et al., 1985, 1995). The 
rationale for the experiments came from finding that under isoflurane anesthesia 
patients demonstrate similar burst suppression in the electroencephalogram as recorded 
during ECT (Langer et al., 1985). The efficacy of isoflurane in treatment resistant 
depressed patients was found to be similar to ECT in these small clinical trials and the 
finding was recently replicated (Langer et al., 1985, 1995; Weeks et al., 2013). Isoflurane 
treatment, however, did not produce as severe cognitive side effects as seen with ECT. 
The potential of isoflurane in the treatment of depression has not been widely studied 
and there are additional studies with controversial findings about the efficacy of burst 
suppression anesthesia in the treatment of depression (García-Toro et al., 2001). It 
remains to be studied if burst suppression is the critical factor in the antidepressant 
effects of anesthesia or ECT and if anesthesia could be used in the treatment of 
depression. 
In addition to anesthetics, the cholinergic muscarinic receptor antagonist scopolamine 
and serotonin agonist psilocybin have demonstrated rapid antidepressant effects in 
depressed patients (Carhart-Harris et al.; Drevets and Furey, 2010; Furey and Drevets, 
2006). The pharmacological effects of these drugs differ from those of ketamine, 
isoflurane and nitrous oxide indicating that the mechanisms underlying rapid 
antidepressant effects are complex and require further characterization.  
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3. AIMS OF THE STUDY 
 
Pharmacological enhancement of brain plasticity could be beneficial in the treatment of 
psychiatric disorders, especially depression. Since TrkB receptor is involved in regulation 
of brain plasticity it could be a favorable target for drug development. Our purpose was 
to develop a method that would be suitable for screening of novel TrkB receptor 
activators or inhibitors or molecules that would enhance the effects of BDNF. In addition, 
we aimed at characterizing further the mechanisms how the already existing TrkB 
activators, the monoaminergic antidepressant drugs, promote TrkB activation. Recently, 
TrkB receptor has been also linked to the rapid antidepressant-like effects of ketamine. 
In addition to ketamine, isoflurane anesthesia has been demonstrated to rapidly reduce 
depression symptoms of treatment resistant depressed patients. Our aim was to examine 
molecular, structural and behavioral effects of isoflurane in rodents to elucidate the 
putative neurobiological basis of the antidepressant effects of isoflurane.  
 
The specific aims of the study were: 
 
1. To develop novel methods to screen for drugs regulating TrkB receptor 
phosphorylation (I) 
2. To elucidate the mechanisms of antidepressant-induced TrkB activation 
(II,III) 
3. To investigate the neurobiological basis of antidepressant effects of isoflurane 
anesthesia (IV) 
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4. MATERIALS AND METHODS 
 
The materials and methods personally used by the author are summarized here. Detailed 
information of the additional materials and methods can be found in the original 
publications.  
4.1 Animals 
Adult (2-4 months) or pup (P5-P21) C57BL/6JRccHsd mice (Harlan Laboratories, 
Venray, Netherland), Bdnf+/−, Bdnf−/−, B6.Cg-Tg(Thy1- YFPH)2Jrs/J (Thy1-YFP, 
Jackson Laboratories, Bar Harbor, ME, USA) and transgenic mice overexpressing flag-
tagged TrkB or truncated TrkB.T1 and their wild type littermates were maintained in the 
animal facility of University of Helsinki, Finland, under standard laboratory conditions 
(21°C, 12-hour light-dark cycle, lights on at 6 A.M.) with free access to food and water. 
Littermates were randomly assigned to different treatment groups. All the experiments 
were carried out according to the guidelines of the Society for Neuroscience and were 
approved by the County Administrative Board of Southern Finland. 
4.2 Drug treatments 
Fluoxetine (HCl salt; Orion Pharma, dissolved in 0,9% NaCl, 30 mg/kg)  was 
intraperitoneally injected to mice and the mice were culled 1 h later (II, SDS-PAGE 
zymography). Isoflurane (Vetflurane®, Virbac) anesthesia was induced with 4% 
isoflurane for 2 min, after which the mouse freely inhaled isoflurane (3,0 % for 1 min, 
then 2 % for maximum of 30 minutes; airflow: 0.3-0.5 l/min) in the chamber of mask. 
Halothane anesthesia was conducted with similar concentrations and protocol as 
isoflurane anesthesia. Body temperature was maintained with a heat pad throughout the 
treatment. Sham mice were kept in the induction chamber for 2 min without isoflurane. 
NBQX (2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide, Tocris 
Bioscience, Bristol, UK) was injected (i.p., 10 mg/kg; dissolved in saline) 10 min before 
sham/isoflurane treatment. Mice were culled by cervical dislocation while still under 
anesthesia or following the described recovery periods after stunning with CO2. Control 
mice were culled by cervical dislocation after stunning with CO2. 
4.3 Cell culture 
4.3.1 Fibroblasts 
TrkB expressing MG87 fibroblasts were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% fetal calf serum (FCS), 1% penicillin/streptomycin, 1% 
l-glutamine and 400 μg/ml G418. The cell line was maintained in a cell incubator (5% 
CO2, 37 °C). 
4.3.2 Primary neuronal cultures 
For the primary neuronal cultures, hippocampi or cortex was dissected from E18 rat 
embryos and the tissue dissociated in papain solution (in mg: 10 DL-Cysteine-HCl, 10 
BSA, 250 glucose, ad 50 ml PBS (pH 7.4); 10 min, 37 °C). Next the cells were triturated 
and suspended in a medium containing 9.8 ml of Ca2+/Mg2+ free HBBS, 1 mM sodium 
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pyruvate, 10 mM HEPES (pH 7.2) and 10 μl DNAse I. The cells were plated onto poly-L-
lysine (Sigma–Aldrich) coated cell culture plates. Neurons were maintained in 
Neurobasal medium supplemented with 2% B27, 1% penicillin/streptomycin and 1% L-
glutamine and fresh medium was added twice a week.  
4.4 Enzyme-linked immunosorbent assay (ELISA) 
4.4.1 Conventional pTrkB ELISA 
Cell homogenates were transferred from culture plates into pre-coated (sc-11-R, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA; 1:500–1000 in Optacoat™; overnight at +4 
°C) and pre-blocked (2% bovine serum albumin (BSA)/phosphate buffered saline-Tween 
20 (PBS-T); 2 h at room temperature) white 96-well Optiplate™ (PerkinElmer Oy, 
Espoo, Finland) plates and 3% BSA/PBS-T (+2 mM Na3VO4 tyrosine phosphatase 
inhibitor) added ad 200 μl. After overnight incubation at +4 °C the wells were washed 
with PBS-T (4 × 300 μl) and anti-phosphotyrosine antibody was added to the wells (in 
house biotinylated PY20; AbD Serotec, Kidlington, UK; 1:1000 in 2% BSA/PBS-T; 
overnight at +4 °C). Following sequential washes and horseradish peroxidase (HRP)-
coupled streptavidin antibody incubation (1:10,000 in 2% BSA/PBS-T; O/N at 4 °C) 100 
μl of enhanced chemiluminescence (ECL) substrate mix was added to the wells and 
luminescence measured with Varioskan Flash plate reader (Thermo Fisher Scientific 
Oy). 
4.4.2 In situ TrkB ELISA 
For the in situ phospho-Trk ELISA, dissociated cells were directly plated onto UV-
sterilized ELISA plates pre-coated (sterile filtered sc-11-R, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA; 1:500–1000 in Optacoat™; overnight at +4 °C) and pre-blocked 
(sterile filtered 2% BSA/PBS-T; 2 h at room temperature). After drug and/or BDNF 
treatment, the plates were put on ice, medium discarded and lysis buffer applied (10–25 
μl). Next, the plates were rigorously shaken in a cold room for 30–60 min (800 rpm, 
Labsystems Wellmix, Thermo Fisher Scientific Oy) after which 3% BSA/PBS-T (+2 mM 
Na3VO4 tyrosine phosphatase inhibitor) was applied ad 200 μl (96-multiwell) or ad 50 
μl (384-multiwell). After overnight incubation at +4 °C, the wells were washed and 
ELISA assay continued as described above. 
4.5 Proof-of-concept small molecule screening 
For the small molecule screening, MG87-trkB fibroblasts were cultured directly on 96-
well ELISA plates. Next day, the cells (at ~80 % confluency) were pre-stimulated with 
vehicle or with Spectrum Collection compounds for 15 min (5 μM; n = 1; +37 °C) using 
Biomek FXp workstation (Beckman Coulter Finland Oy, Helsinki, Finland) and then 
post-stimulated with vehicle or with BDNF (5 ng/ml; +37 °C) for another 15 min using 
Multidrop Combi (Thermo Fisher Scientific Oy). After the stimulations, the medium was 
discarded, cells were lysed in ProteoJET™ membrane protein extraction buffer and 
ELISA analyses run as described. Compounds regarded as hits (response to BDNF ± 3× 
standard deviation (STDEV)) were re-tested in triplicates and the compounds that still 
passed the hit criteria were analyzed in a dose-response assay (0.25, 1, 5, 25 μM; n = 3) 
(inhibitors with and activators without BDNF post-treatment). 
40 
 
4.6 Brain sample collection  
The brain samples were dissected on a cooled dish and homogenized in NP buffer 
(137mM NaCl, 20mM Tris, 1% NP-40, 10% glycerol, 48mM NaF, H2O, Complete 
inhibitor mix (Roche), 2mM Na3VO4). After minimum of 15 min incubation on ice, 
samples were centrifuged (16000 x g, 15 min, +4 °C) and the resulting supernatant was 
collected for further analysis. Sample protein concentrations were measured using Bio-
Rad DC protein assay (Bio-Rad Laboratories, Hercules, CA). 
4.7 Ex vivo stimulations 
The ex vivo BDNF stimulation assay was performed according to Knüsel et al (1994) with 
slight modifications. After dissection the samples were chopped to microslices with 
scalpel. The slices were transferred in fresh tubes with 10% FCS in supplemented 
neurobasal medium and centrifuged (6000 x g, 1 min, +4 °C). Fresh medium was added 
to the slices according to their weight and the slices were resuspended to the medium 
and divided to stimulation tubes. The medium was removed and 300 µl of prewarmed 
(+ 37 °C) neurobasal medium +10% FCS with or without BDNF (Peprotech) or NGF 
(Promega) was added. The tubes were closed and incubated at +37°C for 15 minutes 
gently shaking. Finally the tubes were put on ice, spun down, the medium removed, the 
pellet was rinsed once with PBS and then the samples were homogenized in NP++ buffer.  
4.8 Western blot  
Western blotting analysis was conducted from medial prefrontal cortex (including 
prelimbic and infralimbic cortices), somatosensory cortex and the whole hippocampus. 
Immunoprecipitation (500 μg protein) was carried out using anti-Flag M2 antibody 
(F1804; Sigma-Aldrich). For immunoprecipitation the samples (500 µg protein) were 
rotated overnight with 5 µl of the antibody at +4°C, then 30 µl 50% G-sepharose slurry 
was added (rotation 2 h at +4°C) and the precipitated samples were washed 3x500µl PBS 
+2 mM Na3VO4). The samples were heated in Laemmli buffer for 5 min at +100 °C. 
Immunoprecipitated or unprocessed samples (50 μg protein) were separated with SDS-
PAGE under reducing conditions and blotted onto a PVDF (polyvinylidene difluoride) 
membrane (300mA, 1 hour, 4°C). Membranes were incubated with the following primary 
antibodies: anti-p-TrkBY816 (1:1000; from Dr. Moses Chao, Skirball Institute, NY, USA), 
anti-p-TrkBY816 (#4168; 1:1000; Cell signaling technology (CST)),  anti-p-TrkA/BY490/Y515 
(#9141; 1:1000;CST), anti-p-TrkA/BY674-5/Y706-7 (#4621S; 1:1000; CST), anti-TrkB 
(1:2000; BD Transduction Laboratories, San Jose, CA, USA), anti-p-CREBS133 (#9191S; 
1:1000; CST), anti-p-AktThr308 (#4056S; 1:1000; CST), anti-p-mTORS2481 (#2974S; 
1:1000; CST), anti-p-p70S6KT421/S424 (#9204S; 1:1000; CST), anti-p-4E-BP1T37/46 (#2855; 
1:1000; CST), anti-p-GSK3βS9 (#9336; 1:1000; CST), anti-p-eEF2T56 (#2331; 1:1000; 
CST), anti-Trk (sc-11; 1:1000; Santa Cruz Biotechnology (SCB)) and anti-GAPDH (sc-
25778; 1:10000; SCB).  Further, the membranes were washed with TBS/0.1% Tween 
(TBST) and incubated with horseradish peroxidase conjugated secondary antibodies 
(1:10000 in non-fat dry milk, 1 hour at room temperature; Bio-Rad). After subsequent 
washes, secondary antibodies were visualized using enhanced chemiluminescence (ECL 
Plus, ThermoScientific, Vantaa, Finland) and detected by Fuji LAS-3000 camera (Tamro 
Medlabs, Vantaa, Finland). 
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4.9 SDS-PAGE zymography 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) -zymographty 
was used to examine the activity of tissue plasminogen activator (tPA). For tPA activity 
assay, freshly dissected brain samples were homogenized into buffer consisting of 0.1 M 
Tris-HCl (pH 8.0), 2.5% Triton-X-100, 10 µM leupeptin, 10 µg/ml aprotinin, 1 mM 
phenylmethanesulfonylfluoride (PMSF). Samples and controls (human recombinant 
tPA) were loaded under non-reducing conditions in SDS-PAGE gels ±human 
plasminogen (Sigma-Aldrich) and pre-heated non-fat dry milk at run at low current 
(∼15–20 mA) overnight (O/N) at cold bath. Next the gels were rinsed thoroughly with 
2.5% Triton X-100 to remove SDS and allow proteins to renaturate. Then the gels were 
rinsed thoroughly with 10 mM CaCl2 in 50 mM Tris-HCl (pH 7.6) to remove Triton X-
100 and the caseinolysis was allowed to occur by incubating the gels at +37°C for 16–24 
h in the same solution. Caseinolytic areas were shown as translucent areas when the gels 
were stained with Coomassie Brilliant Blue. 
4.10 Immunohistochemistry and dendritic spine analysis  
The density of dendritic spines was analyzed in fixed cortical sections from B6.Cg-
Tg(Thy1- YFPH)2Jrs/J (Thy1-YFP, Jackson Laboratories, Bar Harbor, ME, USA)  mice. 
Animals were transcardially perfused at 24 hours after isoflurane/sham treatment under 
deep pentobarbital anesthesia with 4% paraformaldehyde in phosphate buffer (PB) 0.1M 
and post-fixed for 1 hour. Floating sections (50 μm thick) were cut using a vibratome (VT 
1000S, Leica, Germany) and processed for immunohistochemistry as follows: PBS wash, 
blocking for 1 h (10% normal goat serum in PBS/0,2% Triton-X100), anti-YFP antibody 
overnight (chicken polyclonal 1:1000; Abcam), PBS wash, Alexa-488-conjugated goat 
secondary antibody for 2 h (1:200; Invitrogen), PB wash and mounting using 
fluorescence medium (Dako). Images were obtained using a confocal microscope (Leica 
TCS SP5II HCS), and pyramidal neurons from the medial prefrontal cortex (mPFC) and 
somatosensory cortex (SSCx) were selected with the following criteria: intense 
fluorescence, soma located in layer V, and primary apical dendrite >200 μm long. We 
imaged the dendrites in three ~65 μm long segments (proximal/medial/distal). We 
distinguished different types of dendritic spines: (i) stubby (protrusion length <1.5 μm); 
(ii) mushroom (clearly visible head with a diameter >1.5 times the average length of the 
neck, and the total length of the protrusion <3 μm) and; (iii) filopodia/thin (the length 
of the protrusion >3 μm or non-headed 1.5-3 μm protrusion).  
4.11 Quantitative real-time polymerase chain reaction (qPCR) 
RNA was extracted using Trizol® reagent (Thermo Scientific) and treated with DNAse I 
mix (Fermentas GmbH) and then reverse transcribed using oligo(dT) primer and 
RevertAid First Strand cDNA synthesis kit (Thermo Scientific). The control reactions 
without reverse transcriptase were also performed. The amount of cDNA was quantified 
using Maxima SYBR green qPCR master mix (Thermo Scientific) by real-time PCR. Total 
Bdnf cDNA was amplified using the following primers: 5´- 
GAAGGCTGCAGGGGCATAGACAAA-3´ and 5´-TACACAGGAAGTGTCTATCCTTATG-
3´. For normalization GAPDH cDNA levels were analyzed with the following primers 5 ́- 
GGTGAAGGTCGGTGTGAACGG-3´ and 5 ́-CATGTAGTTGAGGTCAATGAAGGG-3´. Ct 
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values from each sample were obtained using the LightCycler 480 software (Roche 
Diagnostics Ltd.). 
4.12 Behavioral experiments  
4.12.1 Forced swim test 
For the forced swim test a mouse was placed into a glass cylinder (diameter 19 cm, height 
24 cm) filled with water (21±1°C) to the height of 14 cm. The latency to the first 
immobility period (passive floating, when the animal was motionless or doing only slight 
movements with tail or one hind limb) and immobility during the last 4 minutes of the 6 
min test was measured.  
4.12.2 Open field test 
The open field test was performed for 30 min in an illuminated (300 lux) transparent 
acrylic cage (length 28.5 × height 8.5 × width 20 cm) (Med Associates). Interruptions of 
infrared photo beams were used to calculate the overall distance traveled (cm) and time 
spent in the center of the arena. 
4.12.3 Water maze 
Noldus EthoVision XT 10 program (Noldus Information Technology, The Netherlands) 
was used for monitoring the mouse behavior in the water maze test. The system consisted 
of a black circular swimming pool (Ø 120 cm) and a transparent escape platform (Ø 10 
cm) submerged 0.5 cm under the water surface in the centre of one of four imaginary 
quadrants. The animals were released to swim (in random positions) from all three other 
quadrants facing the wall and the time to reach the escape platform (maximum time 60 
s) and the swimming distance were measured in every trial. Two training blocks 
consisting of three trials each were conducted daily. The interval between trials was 4-5 
min and between training blocks about 4 hours. The hidden platform remained in a 
constant location for 3 days (6 initial training sessions) and was thereafter moved to the 
opposite quadrant for 2 days (4 reverse training sessions).  
4.13 Statistical tests 
The statistical analyses were conducted with unpaired two-tailed Student’s t-test, Mann 
Whitney U test (non-normally distributed data), one-way analysis of variance (ANOVA) 
or two-way ANOVA. Tukey HSD, Newmann-Keuls or Dunnett’s test were used for post 
hoc analysis. Statistically significant p value was set to ≤ 0.05. The results are 
represented as mean ± SEM (standard error of mean). 
 
 
 
 
 
43 
 
5.RESULTS 
5.1 Development of phospho-Trk ELISAs (I) 
Enzyme-linked immunosorbent assay (ELISA) is a widely used method in molecular 
biology. Sandwich ELISA is a method conducted on a multiwell plate where capture 
antibody is immobilized to the bottom of the plate. After sample incubation the non-
specifically bound proteins are washed away and a secondary antibody coupled to an 
enzyme is added. The amount of the protein of interest captured by the primary antibody 
can then be measured by adding a substrate to the enzyme and detecting the enzymatic 
reaction by colorimetric or luminometric assays. We set up a conventional sandwich 
ELISA where we use Trk receptor antibody as a capturing antibody and biotinylated 
phosphotyrosine antibody as a secondary antibody. A HRP-coupled streptavidin 
antibody is used as a tertiary antibody and after adding substrate to the HRP the amount 
of tyrosine phosphorylated Trk receptors can be measured. This conventional phospho-
Trk ELISA was used in publications I,II and III in several experimental conditions to 
detect the phosphorylated Trk receptors from cultured neurons and MG87-TrkB cells.  
To optimize the ELISA protocol we tested different coating conditions, primary 
antibodies and lysis buffers and found that Optacoat buffer, SC-11 rabbit polyclonal Trk 
antibody and ProteoJet lysis buffer significantly increased the signal to noise ratio when 
compared to other buffers or antibodies (I). 
Next, we modified the standard sandwich pTrk ELISA to an in situ format where all the 
steps including cell culture, stimulation, antibody incubation and detection can be done 
in the same plate (I). Transferring cell lysate from the cell culture plate to the ELISA plate 
is time consuming and laborious and can be avoided in the in situ ELISA.  In the in situ 
pTrk ELISA MG87 fibroblasts overexpressing TrkB receptors are cultured on UV-
sterilized OptiplateTM HB 96 or 384 well plates that are previously coated with SC-11 Trk 
antibody and blocked. The cells are incubated 24 hours after which they can be 
stimulated. After the stimulation lysis buffer is added to the wells and the plate is 
vigorously shaken at + 4 OC for 1 h. When the cells have been lysed the ELISA protocol is 
continued similarly to the conventional pTrk ELISA.  
We also showed that the in situ ELISA can be upscaled from 96 to 384 well plate making 
it suitable for high throughput screening (I). As a proof of concept we performed a 
screening of a library of 2000 compounds and identified several compounds that were 
able to induce TrkB phosphorylation or inhibit or potentiate BDNF-induced TrkB 
activation. Among the TrkB activators was betamethasone valerate and epoxygedunin 
and among the inhibitors for example tomatine, gramicidin and fenbendazole. 
 
 
 
44 
 
5.2 Mechanisms of antidepressant induced TrkB activation - BDNF and 
serotonin transporter (SERT) are dispensable for TrkB activation by 
antidepressant drugs (II) 
Saarelainen et al. (2003) first described that antidepressant drug imipramine can induce 
TrkB receptor phosphorylation in the mouse hippocampus and frontal cortex and later 
it was demonstrated that TrkB activation appears to be a common feature of ADs with 
different pharmacological properties (Rantamäki et al., 2007). How ADs promote TrkB 
activation was, however, unknown and especially it remained unclear whether BDNF is 
required for the effect. It is impossible to directly measure BDNF release in the brain and 
thus TrkB phosphorylation has been used as a surrogate measure for BDNF release. TrkB 
activation can occur, however,  independently of BDNF via transactivation (Lee and 
Chao, 2001). It has been also suggested that antidepressant amitriptyline and 7,8—
dihydroxyflavone are direct TrkB receptor agonists (Jang et al., 2009, 2010). 
In addition to the full-length TrkB receptor (145 kDa), ADs seem to induce 
phosphorylation of a protein ~105 kDa in size (II). It has been suggested to be an 
immaturely glycosylated form of the TrkB receptor and indeed we found that digestion 
with endoglycosidase H, which deglycosylates proteins, reduced the molecular weight of 
the 105 kDa protein (II). To support the assumption that the 105 kDa protein is an 
isoform of TrkB, in TrkB overexpressing mice also the baseline phosphorylation of this 
protein is increased. Furthermore, 1NaPP1 inhibitor treatment of TrkBF616A mutant mice 
decreased also the imipramine-induced phosphorylation of the 105 kDa protein. 
The TrkB activation occurs in 30 minutes after imipramine injection but no changes have 
been detected in the BDNF protein or mRNA levels after acute AD treatment, suggesting 
that local release of BDNF could mediate the effect (Nibuya et al., 1995b; Rantamäki et 
al., 2007; Saarelainen et al., 2003). It has been shown in hippocampal slices that 
proBDNF and BDNF can be released together with tPA in response to increased neuronal 
activity (Pang et al., 2004). tPA cleaves proBDNF to BDNF and thus could increase the 
BDNF concentration in the synaptic cleft resulting in increased TrkB phosphorylation. 
We studied with SDS-PAGE zymography if fluoxetine treatment (1h) increases the 
enzymatic activity of tPA in the hippocampus but no difference in the tPA activity or 
BDNF protein levels were found between saline and fluoxetine treated animals (II). More 
importantly, imipramine activated TrkB in the brains of BDNF cKO animals whose 
hippocampal BDNF levels are below detection limits. This indicates that antidepressants 
can activate TrkB receptor also in the absence of BDNF.  
Since the TrkB receptor activation by ADs occurred independently of BDNF we 
investigated if ADs would facilitate adenosine receptor –mediated TrkB transactivation 
(II). Previously, adenosine A2A receptors have been shown to transactivate TrkB 
receptors in vitro and in vivo (Lee and Chao, 2001; Wiese et al., 2007). Blocking 
adenosine A2A receptors, however, did not affect the ability of imipramine to induce TrkB 
phosphorylation suggesting that adenosine mediated transactivation is not involved in 
the antidepressant-induced TrkB activation (II). To study the possibility that ADs act as 
direct agonists of TrkB receptor and can induce the TrkB phosphorylation similarly to 
BDNF, we stimulated hippocampal and cortical neuron cultures with imipramine or 
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amitriptyline but no increase in TrkB phosphorylation was detected (II). These results 
indicate that antidepressants apparently are not able to directly bind to TrkB receptors.  
SERT is the main pharmacological target for fluoxetine and we examined if the effects of 
fluoxetine on TrkB phosphorylation require binding to SERT. In the SERT knockout 
mice fluoxetine induced TrkB phosphorylation similarly to wild type mice, indicating 
that SERT is not required for fluoxetine to activate TrkB receptors (II). Moreover, the 
extracellular 5-HT concentration in SERT knockout mice is significantly increased but 
no change at baseline TrkB phosphorylation was detected, suggesting that 5-HT does not 
directly induce TrkB activation. We further examined the effects of monoamines on TrkB 
phosphorylation in cortical neuron cultures but 15 minutes incubations with 10 nM-10 
µM concentrations of noradrenaline or 5-HT did not affect TrkB phosphorylation.  
5.3 Developmental regulation of TrkB activation by antidepressant drugs and 
BDNF (III) 
Previously it has been shown that BDNF-induced TrkB phosphorylation is 
developmentally regulated (Knusel et al., 1994). We were able to reproduce these 
findings using BDNF ex vivo stimulation in microslices prepared from mouse 
hippocampus of different developmental stages (P5-P21) demonstrating that 
responsiveness of TrkB to exogenous BDNF decreases dramatically after P12 (III). 
Intriguingly, we further discovered that at this particular developmental time point the 
antidepressant drug imipramine starts to activate TrkB receptor in the mouse PFC and 
hippocampus when injected intraperitoneally (30 mg/kg), whereas at the earlier 
timepoints imipramine did not increase TrkB phosphorylation from the baseline. Also 
imipramine-induced phosphorylation of CREB, which is activated downstream of the 
TrkB-PLCγ pathway, appeared at P12. To demonstrate the role of BDNF in the TrkB 
activation in vivo, we measured the baseline TrkB phosphorylation levels in BDNF 
heterozygous knockout mice and BDNF knockout mice and found that at P11 the TrkB 
phosphorylation was significantly lower in BDNF heterozygous mice and knockout mice 
when compared to wild type mice. Intriguingly, in the adulthood there was no difference 
in TrkB phosphorylation levels in BDNF conditional knockout or heterozygous knockout 
mice and wild type mice, supporting the finding that BDNF is critical for the baseline 
phosphorylation of TrkB at early postnatal age but dispensable in the adulthood. 
To examine what could underlie the developmental switch in the TrkB responsiveness to 
BDNF and ADs we conducted several experiments. The expression of the truncated 
isoform of TrkB increases at the same developmental timepoint when the responsiveness 
of TrkB to BDNF diminishes (Fryer et al., 1996). We used transgenic mice lacking the 
TrkB.T1 receptor to examine the role of TrkB.T1 receptor in the TrkB responsiveness to 
BDNF and ADs (III). The phosphorylation of TrkB in response to BDNF decreased 
similarly in the TrkB.T1 KO mice microslices as in wild type mice microslices, indicating 
that TrkB.T1 receptor expression does not regulate the activation of the full-length TrkB 
receptor by exogenous BDNF. Also in adult TrkB.T1 KO mice imipramine induced TrkB 
phosphorylation normally. 
Chronic treatment with fluoxetine has been shown to promote neuronal plasticity and 
restore more immature developmental stage in the adult rodent brain (Karpova et al., 
2011; Maya Vetencourt et al., 2008). We tested if chronic fluoxetine treatment (21 days) 
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could restore the TrkB responsiveness to BDNF in adult mice but no difference between 
fluoxetine-treated and saline-treated animals was observed, implicating that the 
juvenating effects of fluoxetine were not enough to restore the responsiveness of TrkB to 
ex vivo BDNF (III). 
By using a cell-free kinase assay we investigated if TrkB receptor itself had undergone 
some structural modifications during development that could explain the decrease in 
BDNF responsiveness (III). BDNF stimulation of cell-free lysates from adult brain in the 
presence of ATP induced TrkB phosphorylation, demonstrating that the receptor can still 
be activated by BDNF. In addition, NGF ex vivo stimulation could readily induce TrkA 
activation at P24 suggesting that the ability of neurotrophins to penetrate the tissue is 
not the reason for the reduced responsiveness of TrkB to BDNF and that the 
developmental regulation may be a specific trait for BDNF. 
 
5.4 Isoflurane activates TrkB signaling, enhances synaptic plasticity and 
induces antidepressant-like behavior (IV) 
Volatile anesthetic isoflurane has previously been shown to relieve depression symptoms 
in treatment-resistant depressed patients (Langer et al., 1985, 1995; Weeks et al., 2013). 
We examined the ability of isoflurane to affect BDNF-TrkB signaling and found that 
isoflurane anesthesia readily activates TrkB receptor by inducing phosphorylation of the 
catalytic domain Y706/7 and PLCγ binding site Y816 (but not Shc binding site Y515) of 
TrkB (IV). In the prefrontal cortex and hippocampus of anesthetized mice 
phosphorylations of CREB, Akt (not hippocampus), mTOR (not hippocampus), P70S6K, 
4EBP-1 and GSK3beta were significantly increased. These TrkB downstream signaling 
molecules have been previously shown to be  phosphorylated by conventional 
antidepressant drugs and especially by rapid-acting antidepressant ketamine (Li et al., 
2010; Rantamäki et al., 2007; Saarelainen et al., 2003). Interestingly, similarly to 
antidepressant drugs, isoflurane does not induce TrkB phosphorylation in the 
hippocampus of mouse pups at P8 (Fig. 5). 
 
Fig 4. Isoflurane anesthesia did not induce TrkB activation in the prefrontal cortex or hippocampus 
of P8-9 wild type mice pups. Abbreviations: CTRL, control treatment; ISO, isoflurane treatment 
15 min; PFC, prefrontal cortex; HC, hippocampus; TrkB.FL, full-length TrkB receptor.  
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The activation of TrkB by isoflurane occurs quickly, within few minutes (IV). When 
measured 15 minutes after the end of the anesthesia the phosphorylation of TrkB has 
returned close to the baseline indicating that the phosphorylation is transient. Activation 
of the signaling molecules seems to be regulated in a similar manner, since the activation 
of the mTOR and CREB occurs already in 2 minutes. Pretreatment with AMPA receptor 
antagonist NBQX did not affect the ability of isoflurane to activate TrkB receptor and the 
downstream signaling molecules, suggesting that the effects of isoflurane on TrkB 
signaling are not mediated via AMPA receptors.  
Importantly, isoflurane activated TrkB receptors also in the hippocampus of BDNF 
conditional knockout mice, suggesting that TrkB activation by isoflurane occurs via 
transactivation and is not mediated by BDNF (IV). To investigate the putative 
mechanisms underlying the isoflurane-induced TrkB transactivation we conducted a 
mass spectrometry analysis of proteins interacting with TrkB in the adult brain. We 
found that PSD93, a synaptic scaffolding protein, interacts with TrkB. Since volatile 
anesthetics have been shown to promote disruption of PSD93 and PSD95 interaction 
from NR2B-subunits of NMDA receptors in vitro (Fang et al., 2003), we investigated if 
isoflurane regulates the interaction between PSD93 and TrkB. We stimulated RN33 
(immortalized raphe nuclei neuronal precursor cell line) cells with isoflurane and found 
that isoflurane dose-dependently promoted disruption of TrkB-PSD93 interaction. 
Moreover, reducing PSD93 expression in RN33 cells with siRNA increased the basal 
TrkB phosphorylation levels, suggesting that releasing TrkB from the PSD93 protein 
complex facilitates its activation. Interestingly, naïve PSD93 knockout animals showed 
antidepressant-like behavioral effect in the FST. 
To further elucidate the mechanisms that could be involved in the TrkB activation by 
isoflurane we examined the Src family kinases. Previously, the Src family kinases have 
been shown to be involved in the TrkB transactivation (Rajagopal and Chao, 2006). In 
vitro, isoflurane treatment increased association of the activated Fyn with TrkB and 
pretreatment with PP1 (protein phosphatase 1; Src inhibitor) abolished the effects of 
isoflurane on TrkB phosphorylation (IV).  
Since the signaling pathways activated by isoflurane have been linked with 
synaptogenesis, cell survival and plasticity we examined the effects of isoflurane 
anesthesia on LTP in Schaffer collaterals in hippocampus. Indeed, we found that in slices 
from mice that were anesthetized for 30 minutes 24 hours before the electrophysiological 
recordings the LTP was enhanced (IV). Interestingly, the LTP enhancement could be 
blocked with picrotoxin pretreatment, suggesting that GABAergic component is 
involved. Moreover, we found that GABAergic excitability is increased at this time point 
and this finding was supported by increased FosB immunoreactivity (marker of neuronal 
activity) in GABAergic cells of CA1 area of the hippocampus.  
The increase in LTP was not, however, accompanied by an increase in hippocampal 
dendritic spine number (IV). In addition, even though signaling pathways linked with 
synaptogenesis are clearly activated in the PFC during the anesthesia, no significant 
differences were seen in dendritic spine number or morphology in the PFC either. 
TrkB signaling has been implicated in the antidepressant-like behavioral effects in the 
FST. Since isoflurane robustly activates TrkB signaling, we tested if isoflurane produces 
a behavioral response in the FST (IV). Indeed we found that isoflurane decreased the 
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immobility time indicating an antidepressant-like phenotype. Interestingly, this 
behavioral response was abolished in the TrkB.T1 overexpressing mice suggesting that 
TrkB signaling is necessary for the behavioral effects of isoflurane in the rodents. 
To further study the behavioral effects of isoflurane we used the learned helplessness 
model. Isoflurane produced a decrease in the escape latency if it was administered 24h 
after the pretest and the actual test was conducted 6 days after the anesthesia indicating 
an antidepressant-like effect (IV). We also examined the ability of isoflurane to 
counteract the effects of chronic neuropathic pain on behavior of sciatic nerve cuffed 
mice. After 8 weeks of sciatic nerve cuffing the mice showed increased latency to eat the 
pellet in the novelty suppressed feeding test. Markedly, the anxiodepressive behavioral 
phenotype was normalized with a single isoflurane anesthesia. These data implicate that 
isoflurane produces antidepressant-like behavioral phenotype and may have rapid and 
long-lasting antidepressant effects similar to ketamine.  
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6. DISCUSSION 
TrkB neurotrophin receptor is an interesting target for drug development. The receptor 
is able to activate downstream signaling cascades that facilitate neuronal excitability and 
regulate translation and transcription of proteins promoting neuronal survival, 
proliferation, differentiation and plasticity (Huang and Reichardt, 2003). Impaired 
brain plasticity has been linked to many brain disorders, including depression, stroke 
and neurodegenerative disorders, and promoting TrkB activity could be beneficial in 
these conditions (Castrén and Rantamäki, 2010). Delivering exogenous BDNF to the 
patients is difficult, since the neurotrophin cannot reach the brain if taken orally and 
even injecting it directly to the brain does not guarantee its efficacy because of its poor 
tissue penetrance (Mufson et al., 1994). Developing drugs that directly target the TrkB 
receptor would be a possible approach to circumvent these issues.  
We developed an in situ ELISA method that is suitable for screening of TrkB activators 
and inhibitors (I). The in situ ELISA allows skipping of some laborious parts of the 
conventional ELISA protocol and provides a possibility for high throughput screening, 
also for industrial purposes. We showed that the phosphoTrk ELISA works in 384 well 
plate format and applying it even to 1536 well plate format could be possible. Previously, 
primary sensory neurons have been cultivated on ELISA plate (Balkowiec and Katz, 
2000), and our purpose was to further develop the in situ ELISA to be suitable for 
primary neurons, however, finding optimal conditions to support the survival of the 
primary neurons in the ELISA plate for long enough was not yet possible. 
The in situ ELISA method can also be used for discovering compounds that facilitate the 
effects of BDNF. A compound that would enhance the effects of endogenous BDNF would 
be physiologically relevant and allow more specific targeting of the drug effect. Activating 
TrkB signaling randomly all over the brain could promote risk for epileptogenic activity 
and randomly strengthen synapses creating more “noise” in the neuronal networks. Yet, 
activation of TrkB receptor independently of BDNF could be useful especially in the 
situations where the expression or release of BDNF is reduced, such as in patients with 
BDNF met/met polymorphism. 
Intriguingly, TrkB activating drugs already exist and are widely used by millions of 
people – the antidepressant drugs. It has been previously demonstrated that 
antidepressant drugs can activate TrkB receptor, at least in the rodent brain (Rantamäki 
et al., 2007; Saarelainen et al., 2003). The clinical efficacy of different ADs is fairly 
similar and their primary target in the brain are the widely projecting monoaminergic 
systems. Even though the ADs primarily target the monoamines, they have effects that 
are not directly mediated via the monoaminergic system. Especially the fact that ADs 
require weeks before their antidepressive effects in humans appear, even though their 
effects on the monoamines are acute, has evoked interest in examining the effects of 
these drugs on targets outside the monoaminergic systems. The neurotrophin and 
network theories of depression and antidepressant action suggest that brain plasticity is 
involved in the pathophysiology of depression and in antidepressant action (Castrén and 
Hen, 2013; Duman and Monteggia, 2006). One of the mediators of the plasticity-
inducing effects of ADs is BDNF, which  acts through TrkB (Karpova et al., 2011; Maya 
Vetencourt et al., 2008). We examined the mechanism of antidepressant-induced TrkB 
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activation and showed that it occurs independently of BDNF and monoamines, 
suggesting that ADs transactivate TrkB receptor (II).  
Neuronal activity is an important regulator of TrkB expression and localization on cell 
surface (Du et al., 2000; Merlio et al., 1993) but transactivation of the receptor could 
occur also in the absence of increased neuronal activity. In addition to receptors on the 
cell surface also receptors residing inside the cell could be transactivated (Schecterson 
and Bothwell, 2010). Activation of the intracellular pool of the TrkB receptors could 
theoretically produce stronger response than the BDNF-dependent activation of limited 
amount of cell surface receptors. Transactivation of the intracellular receptors could also 
promote activation of immature Trk receptors. AD (and isoflurane) treatment constantly 
induced phosphorylation of an unknown 105 kDa protein that we assume to be an 
immaturely glycosylated form of TrkB. Glycosylation of the receptor can inhibit ligand-
independent activation of the receptor, and it has been shown that ERK pathway is not 
activated via the immaturely glycosylated TrkA receptor (Watson et al., 1999a). Since 
ADs transactivate TrkB receptor and do not induce signaling via ERK pathway, this 
further supports the possibility that immaturely glycosylated form of the receptor is 
activated by these drugs. Furthermore, in humans an N-terminal truncated form of TrkB 
receptor is expressed and it is not targeted to the membrane but can be phosphorylated 
(Luberg et al., 2010). 
In addition, it is not known if TrkB transactivation promotes retrograde transport of the 
activated receptors toward the soma. The retrograde transport has been implicated to be 
important for the survival-promoting effects of neurotrophins in the PNS (Watson et al., 
2001). Nonetheless, increased CREB phosphorylation indicates that proteins in the soma 
are also activated by ADs and isoflurane (II, IV). Transactivation of the TrkB receptor by 
ADs does not activate the Shc binding site (Y515) of the receptor (II) that is readily 
phosphorylated upon BDNF binding to the receptor (Segal et al., 1996). In addition, ADs 
did not induce Akt or ERK activation that are in the canonical neurotrophin signaling 
pathway mediated via the Shc binding site (II). The lack of Y515 phosphorylation could 
be related to the conformational properties of the receptor when transactivated or to the 
possibly different subcellular compartment where the transactivated receptors are 
localized. Antidepressant drugs, thus, do not induce completely similar TrkB activation 
as BDNF.  
In addition to conventional ADs we found that isoflurane anesthesia can induce TrkB 
receptor phosphorylation in the adult rodent brain (IV). The TrkB phosphorylation was 
induced also by other inhalation anesthetics, sevoflurane and halothane, suggesting that 
the effect may be common to all anesthetics. Similarly to ADs, TrkB and CREB are 
activated during isoflurane anesthesia (Rantamäki et al., 2007). The TrkB activation by 
isoflurane occurs already in couple of minutes, which is more quickly than by ADs (II,IV). 
The more rapid effect of isoflurane is probably related to the different kinetics of volatile, 
inhalation anesthetic when compared to intraperitoneally injected drugs. Interestingly, 
in contrast to ADs (Li et al., 2010), isoflurane can activate Akt and mTOR-P70S6K-
4EBP1 –signaling in the PFC (IV). This signaling pathway has been previously shown to 
be involved in the antidepressant-like behavioral effects and the rapid synaptogenesis 
enhancing effects of ketamine (Li et al., 2010). Even though ADs and isoflurane are able 
to activate the TrkB receptors, the differences in the activated signaling cascades could 
explain some of the disparities in their effects. Isoflurane for example did not regulate 
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the activity of EEF2 that has been previously shown to be involved in the behavioral 
effects of ketamine (Autry et al., 2011). Moreover, AMPA receptor blockade by NBQX did 
not prevent the isoflurane-induced signaling effects, suggesting that AMPA receptor-
mediated effects are not critically involved in the regulation of TrkB signaling by 
isoflurane (IV). However, AMPA receptor has been crucially linked to the 
antidepressant-like effects of ketamine (Li et al., 2010; Maeng et al., 2008; Zanos et al., 
2016).  
The ability of ketamine to induce rapid increase in the number of dendritic spines has 
been suggested to underlie its rapid antidepressant effects (Li et al., 2010, 2011). Even 
though the synaptogenesis-related signaling is robustly activated by isoflurane, we were 
not able to demonstrate any increase in dendritic spine number in isoflurane treated 
mice when examined 24 hours after the anesthesia (IV). Moreover, activity-dependent 
secretion of BDNF has been linked to the synaptogenesis-promoting effects of ketamine, 
since the ketamine-induced increase in dendritic spines was abolished in BDNF 
heterozygous knockout mice (Liu et al., 2012). The ability of isoflurane to transactivate 
TrkB independently of BDNF could be involved in the differerential effects of isoflurane 
and ketamine on spines. Futhermore, it would have been important to include ketamine 
as a positive control in the experiments, since the effects of ketamine on dendritic spines 
in previous studies have been demonstrated mainly in rats (Li et al., 2010, 2011) and we 
used mice. In addition, stress pretreatment could have been required, since ketamine has 
been shown to counteract the stress-induced downregulation in the spine number (Li et 
al., 2011). Previously, however, general anesthesia has been shown to promote 
synaptogenesis in rats only at certain developmental stage (~P16) but not in the 
adulthood, supporting our findings on naïve adult animals (Briner et al., 2010, 2011; Roo 
et al., 2009). The negative effects of anesthetics on dendritic spine density have been 
demonstrated in rodents at early postnatal age (<P10) (Briner et al., 2011) and since the 
developmental shift also in TrkB activation by isoflurane occurs around this same time 
point, it is tempting to speculate that TrkB signaling could be involved in the 
synaptogenesis-promoting effects of isoflurane. 
The developmental shift in the TrkB response to BDNF and ADs occurs around P12 (III). 
Even though in the adult rodent brain ADs induce TrkB activation, they do not activate 
TrkB receptors when injected to mice at early postnatal age (III). This same applies also 
for isoflurane, since isoflurane anesthesia at P8-9 does not produce TrkB activation (Fig 
5.). The developmental shift in the TrkB activation is not related to changes in the 
structure of the receptor itself but could be explained by changes in the TrkB interacting 
partners capable of regulating the activation and localization of the receptor (III). We 
have not been able to demonstrate TrkB activation by ADs in cultured hippocampal or 
cortical neurons and it is possible that the lack of proper interacting partners at the 
neuronal cells derived from embryonic rat brain could be an explanation. Also the TrkB 
transactivation by ADs may require functional neuronal network that would respond to 
AD treatment in a complex manner recruiting e.g. G-protein coupled receptors, reducing 
the activity of protein phosphatases or affecting general neuronal activity that would then 
eventually lead to TrkB activation. Thus, TrkB transactivation by ADs may require 
processes and mediators that emerge only after certain developmental stage. 
The lack of TrkB activation in cell culture by drugs that can promote TrkB activation in 
vivo complicates the study of the mechanisms of AD-induced TrkB activation in detail 
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using cultured cells. This also has to be taken into account when using the cell-culture 
based in situ ELISA for screening of TrkB regulating drugs. Nonetheless, the maturation 
of the cultured neurons (or other cells), the cell line used and general culture conditions 
can affect the ability of different compounds to activate TrkB receptor. Previously e.g. 
amitriptyline and 7,8-DHF have been shown to activate TrkB receptor in vitro (Jang et 
al., 2009, 2010) and also in our studies we were able to detect isoflurane-induced TrkB 
activation in RN33 cells (IV). 
In addition to the developmental shift in the TrkB activation by ADs, the ability of 
exogenous BDNF to activate TrkB receptor in ex vivo context is developmentally 
regulated (III). Importantly, the reduction in BDNF-induced TrkB activation occurs at 
the same time point when the AD effect appears (~P12). Changes in the interactome 
could also explain the lack of BDNF effect if there are interacting proteins capable of 
preventing the conformational changes of the receptor upon BDNF binding or the 
autophosphorylation of the TrkB receptors. We did not examine in this study whether 
BDNF injection directly to hippocampus of adult mice would increase TrkB activation. 
The baseline TrkB activation in the brain of BDNF conditional knockout or heterozygous 
knockout mice is comparable to wild type mice suggesting that BDNF is not regulating 
the basal level of TrkB phosphorylation in the adulthood (III). In studies where BDNF is 
injected to the brain, its ability to activate TrkB receptor is not normally investigated, 
however, in the study by Guo et al. (2014) BDNF injection to adult rat hippocampus could 
promote phosphorylation of the tyrosine 515 of TrkB. Thus, it is not known for sure if the 
reduction in TrkB activation by BDNF is a special feature of the ex vivo treatment of brain 
microslices and if it applies or not in vivo. 
In addition to the activation of molecules linked to synaptogenesis, the enhanced 
hippocampal LTP 24 hours after isoflurane anesthesia could be accompanied by 
increased mushroom spine number. Yet, we did not find any difference in the spine 
morphology between isoflurane and sham treated animals (IV). Interestingly, we found 
that picrotoxin pretreatment could block the enhanced LTP by isoflurane, which 
indicates that changes in the GABAergic system are involved in the effects of isoflurane. 
This was further supported by the finding that the GABAergic excitability was enhanced 
and the activity of the inhibitory interneurons was increased 24 hours after isoflurane 
treatment. The explanation for the lack of changes in the excitatory spines could be that 
the changes occur rather in the amount and/or strength of the inhibitory synapses than 
in the excitatory synapses.  
The changes in the neuronal network excitability could underlie the long-lasting 
behavioral effects of isoflurane. The long-lasting effects of isoflurane on rodent behavior 
were demonstrated in the learned helplessness model, where a single isoflurane 
treatment produced an antidepressant-like effect when the test was conducted 6 days 
after the treatment (IV). To show that isoflurane has more rapid effects than 
conventional ADs we used novelty suppressed feeding test. The conventional ADs require 
weeks of administration before they produce an effect in the novelty suppressed feeding 
test (David et al., 2009), but a single isoflurane treatment only 12 hours before the test 
was enough to normalize the behavior of the mice in the neuropathic pain model of 
depression (IV). Probably already at this time point changes occur in the network 
function of the isoflurane-treated animals that could underlie the behavioral phenotype. 
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Ketamine has also been suggested to activate TrkB receptor at subanesthetic dose and 
the behavioral effect of ketamine in FST was abolished in TrkB conditional knockout 
mice (Autry et al., 2011). We found that TrkB signaling is required also for the behavioral 
effects of isoflurane in the forced swim test. If TrkB receptor activation is an important 
mediator of the rapid antidepressant effects of ketamine and isoflurane, it is interesting 
why conventional antidepressant drugs then require weeks before their effect arises even 
though they induce TrkB phosphorylation already after single injection. Differences in 
the downstream signaling and the possible rapid increase in BDNF translation have been 
suggested to underlie the differential effects of conventional and rapid-acting ADs (Autry 
et al., 2011; Li et al., 2010). In addition to antidepressant drugs and anesthetics, also 
anticholinesterases galantamine and donepezil, used in the treatment of Alzheimer’s 
disease, can induce TrkB, Akt and CREB activation in mouse hippocampus (Autio et al., 
2011). Thus, drugs with completely different mechanism of action and different 
therapeutic effects produce TrkB activation. All these drugs do not produce 
antidepressant effects in humans, suggesting that TrkB activation solely is not sufficient 
to guarantee antidepressant efficacy. 
We examined the behavioral effects of isoflurane in paradigms that are widely used to 
elucidate the potential antidepressant-like effects of drugs. In general, it is impossible to 
model depression thoroughly in rodents and the models are able to dissect only some 
specific aspects of depression, e.g. anhedonia or coping in stressful situation. The ability 
of drugs to alter the behavior of rodents in these tests allows examination of the critical 
factors that underlie the drug-induced behavioral phenotype in question. These factors 
can then be determined to participate in the effects that the drug mediates. However, it 
is important to be cautious when claiming that the factors regulating rodent behavior are 
crucial for the antidepressant effects in human patients. In addition, even though 
isoflurane anesthesia produces similar changes in rodent behavior as antidepressant 
drugs, to prove that isoflurane relieves depression in humans, and that the effect is rapid 
and long-lasting, requires clinical studies. 
One limitation of our study is that we examined the effects of isoflurane anesthesia only 
on selected proteins downstream of TrkB receptor and on proteins previously linked with 
the rapid-antidepressant effects of ketamine. Apparently, isoflurane can induce 
phosphorylation of a wide range of proteins as was demonstrated by phosphoproteomic 
analysis from isoflurane treated animals (Kohtala et al., 2016) suggesting that all the 
effects are not specific to TrkB signaling pathways,  but may be related to a more general 
increase in protein phosphorylation. The induction of protein phosphorylation may be 
dose-dependent, since subanesthetic dose of isoflurane did not induce similar increase 
in protein phosphorylation (IV).  
Most probably, the antidepressant effects of isoflurane are not induced only by BDNF or 
TrkB but require co-expression of other molecules involved in the regulation of neuronal 
function and plasticity. The effects of conventional ADs and rapid-acting antidepressants 
on these molecules probably differ significantly. Ketamine and isoflurane for example 
robustly affect the NMDA and GABA receptors that directly regulate the neuronal 
network excitability whereas the effects of conventional antidepressant drugs, mediated 
via e.g. elevated levels of serotonin, are modulatory and slower in action. The ability of 
ketamine to rapidly affect synaptic function and plasticity has been suggested to underlie 
its rapid antidepressant effects (Duman et al., 2016). In general, drugs that would 
54 
 
produce rapid effects on synaptic functions in neuronal circuits involved in mood 
regulation could theoretically have antidepressant potential. For example psilocybin, 
which induces psychedelic effects and acutely modulates the functional connectivity of 
the brain, was recently shown to have antidepressant effects in human patients (Carhart-
Harris et al., 2013, 2016). One of the problems related to the therapeutic use of ketamine 
is that the antidepressant effect in human patients is often transient (Krystal et al., 2013).  
Even though acute and rapid regulation of the mood is possible by ketamine, stabilizing 
the functions of the mood networks into a beneficial state appears to be difficult. 
The ability of single isoflurane anesthesia to produce robust effects on the signaling 
pathways and to induce changes in the neuronal excitability, synaptic function and 
rodent behavior may cause problems in experimental procedures where isoflurane 
anesthesia is used. This is important to take into account when planning experiments 
where anesthesia is required. 
The effects of antidepressants and isoflurane on TrkB activation are especially 
interesting in the context of neuronal plasticity. Chronic treatment with antidepressant 
drugs can promote brain plasticity via BDNF–dependent mechanism (Karpova et al., 
2011; Maya Vetencourt et al., 2008). ADs induce TrkB activation already after single 
injection, however, increase in BDNF protein requires chronic treatment (Nibuya et al., 
1995; Rantamäki et al., 2007; Saarelainen et al., 2003). It is possible that the TrkB 
transactivation is not enough to promote the critical period like plasticity demonstrated 
with fluoxetine, since in the study of Karpova et al. (2011) the effects of ADs and 
extinction training on fear removal were abolished in BDNF heterozygous knockout 
mice, even though in these mice ADs induce TrkB receptor activation similarly to wild 
type mice (II). The possible explanation could be that TrkB receptors are activated 
differentially by ADs when compared to BDNF, which could result in lack of activation 
of some important downstream mediators required for the induction of plasticity. BDNF 
can also have off-target effects that are not yet characterized. Currently, the role of TrkB 
receptor in the mechanism of action of antidepressant drugs in humans is not known, 
and solid evidence about the ability of antidepressant drugs to promote brain plasticity 
in humans is lacking. 
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7. CONCLUSIONS 
In this thesis we aimed to examine the mechanisms of antidepressant-induced TrkB 
activation and elucidate the neurobiological basis for the antidepressant effects of 
isoflurane anesthesia. In our experiments we were able to demonstrate that TrkB 
receptor activation by antidepressant drugs can occur independently of BDNF in vivo. 
The exact mechanism of how antidepressant drugs promote TrkB activation, however, 
requires further characterization. The transactivation of TrkB receptor by antidepressant 
drugs seems to differ from BDNF-induced TrkB activation since there are differences in 
the phosphorylation of the tyrosines of TrkB and activation of the downstream signaling 
molecules (Fig 5). Moreover, the TrkB receptor transactivation by ADs appears only after 
certain developmental stage (P12 in mice), when TrkB responsiveness to BDNF is 
reduced, indicating that the effects of ADs during development may differ from those in 
the adult. The ability of isoflurane to promote brain plasticity and to activate signaling 
pathways linked to the mechanisms of action of conventional antidepressant drugs and 
ketamine supports the possibility that isoflurane anesthesia could be a potential 
treatment option for depressed patients.  
                
FIG 5. Activation of TrkB receptors by BDNF, antidepressant drugs and isoflurane. BDNF 
induces phosphorylations of Y515, Y706/7 and Y816 of TrkB, whereas antidepressant drugs and isoflurane 
do not phosphorylate Y515. BDNF activates TrkB downstream signaling pathways including Akt, ERK and 
PLCγ1, whereas antidepressant drugs activate only the PLCγ1 signaling. Isoflurane induces signaling via 
PLCγ1 and Akt. Antidepressant drugs and isoflurane activate the TrkB receptor via transactivation. The TrkB 
responsiveness to BDNF (ex vivo) and antidepressant drugs/isoflurane (in vivo) is developmentally 
regulated so that the responsiveness to BDNF decreases around postnatal day 12 and at this same timepoint 
the TrkB responsiveness to antidepressant drugs/isoflurane appears. Abbreviations: BDNF, brain-derived 
neurotrophic factor; AKT, protein kinase B; ERK, extracellular signal-regulated kinase; PLCγ1, 
phospholipase C gamma 1; pTrkB, phosphorylated TrkB receptor; P0, postnatal day 0; P12, postnatal day 
12; Y, tyrosine. 
The main conclusions are: 
1. Antidepressant drugs transactivate TrkB receptor. 
2. TrkB receptor activation by antidepressant drugs is developmentally regulated. 
3. Isoflurane anesthesia induces molecular, functional and behavioral effects 
similar to those of conventional ADs and ketamine. 
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